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1. INTRODUCTION  
Brucellosis is an ancient and one of the world’s most widespread zoonotic diseases affecting both, public 
health and animal production (Ariza et al., 2007) which is caused by a Gram-negative, facultative 
intracellular bacteria of the genus Brucella. Sicily falls within the Italian regions with the highest 
percentage of positive herds (Pappas et al., 2006). 
The bacteria are transmitted from animals to humans by ingestion through infected food products, direct 
contact with an infected animal, or inhalation of aerosols. The disease is an old one that has been known by 
various names, including Mediterranean fever, Malta fever, gastric remittent fever, and undulant fever. 
Humans are accidental hosts, but brucellosis continues to be a major public health concern worldwide and 
is the most common zoonotic infection (Pappas et al., 2006) 
The target organs and tissues of Brucella spp. are placenta, mammary glands, and epididymis in animal 
reservoir host (Adams, 2002; Xavier et al., 2009; Neta et al., 2010). 
Since 1920, in addition to B. melitensis,B. abortus and B. suis, at least 7 new species have been identified 
as belonging to the Brucella genus with several additional new species under consideration for inclusion 
(Oslen and Palmer, 2014). Now, this genus consists of at least ten nomospecies having characteristic host 
preferences and zoonotic potential. Of these, the following 4 have moderate-to-significant human 
pathogenicity, considered as bioweapons, and are listed as category B priority pathogens by the US Center 
for Disease Control (CDC): 
• Brucella melitensis (from sheep; highest pathogenicity) 
• Brucella suis (from pigs; high pathogenicity) 
• Brucella abortus (from cattle; moderate pathogenicity) 
• Brucella canis (from dogs; moderate pathogenicity) 
 Because the organism is highly infectious, it can be readily aerosolized and outbreaks might be difficult to 
detect due to non-specific symptoms associated with infection (Doganay and Doganay, 2013). The era of 
post-genomic technology offers new and exciting opportunities to understand the complete biology of 
bacteria belonging to Brucella genus. Recently, the genome sequences of B. melitensis, B. suis and B. 
abortus became available. These genomes are very similar in sequence, organization, and structure to other 
ubiquitous Gram-Negative bacteria and few fragments are unique among the genomes. The sequencing and 
annotation of these fragments paved the way for a highly comprehensive and rapid analysis of Brucella 
proteome; also comparative genomics provide insights into aspects of Brucella virulence that were only 
suspected before. 
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1.1 MORPHOLOGY 
Brucella are coccobacilli or short rods 0.6 to 1.5 µm long by 0.5 to 0.7 µm in width. They are arranged 
singly and less frequently in pairs or small groups. The morphology of Brucella is fairly constant except in 
old cultures, where pleomorphic forms may be evident. Brucella are non-motile. They do not form spores, 
flagella, or pili. True capsules are not produced. Brucella are Gram-negative and usually do not show 
bipolar staining. They are not truly acid-fast but resist decolouration by weak acids, thus stain red by the 
Stamp's modification of Ziehl-Neelsen method, which is sometimes used for the microscopic diagnosis of 
brucellosis from smears of solid or liquid specimens. 
1.2 CULTURE AND GROWTH CHARACTERISTICS 
Brucella members are aerobic, but some strains require an atmosphere containing 5-10% carbon dioxide 
(CO2) added for growth, especially on primary isolation. The optimum pH for growth varies from 6.6 to 
7.4, and culture media should be adequately buffered near pH 6.8 for optimum growth. The optimum 
growth temperature is 36-38°C, but most strains can grow between 20°C and 40°C. Brucella require biotin, 
thiamin and nicotinamide. The growth is improved by serum or blood, but haemin (V-factor) and 
nicotinamide-adenine dinucleotide (X-factor) are not required. The growth of most Brucella strains is 
inhibited on media containing bile salts, tellurite or selenite. Growth is usually poor in liquid media unless 
culture is vigorously agitated. Growth in static liquid media favours dissociation of smooth-phase cultures 
to non-smooth forms. Continuous and vigorous aeration will prevent this, provided a neutral pH is 
maintained. In semisolid media, CO2-independent Brucella strains produce a uniform turbidity from the 
surface down to a depth of a few millimetres, while cultures of CO2-requiring strains produce a disk of 
growth a few millimetres below the surface of the medium. On suitable solid media Brucella colonies are 
visible after 2 days incubation. After 4 days incubation, Brucella colonies are round, 1-2 mm in diameter, 
with smooth (S) margins, translucent and a pale honey colour when plates are viewed in the daylight 
through a transparent medium. When viewed from above, colonies appear convex and pearly white. Later, 
colonies become larger and slightly darker. Smooth Brucella cultures, especially B. melitensis cultures, 
have a tendency to undergo variation during growth, especially with subcultures, and dissociate to rough 
(R) forms, and sometimes mucoïd (M) forms. Colonies are then much less transparent with a more 
granular, dull surface (R) or a sticky glutinous texture (M), and range in colour from matt white to brown in 
reflected or transmitted light. Intermediate (I) forms between S, R and M forms may occur in cultures 
undergoing dissociation to the non-smooth state. Changes in the colonial morphology are generally 
associated with changes in virulence, serological properties and phage sensitivity. 
1.3 ANTIGENIC CHARACTERISTICS 
All smooth Brucella strains show complete cross-reaction with each other in agglutination tests with 
unabsorbed polyclonal antisera, a cross-reaction which does not extend to non-smooth variants. Cross-
reactions between non-smooth strains can be demonstrated by agglutination tests with unabsorbed anti-R 
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sera. Lipopolysaccharide (LPS) comprise the major surface antigens of the corresponding colonial phase 
involved in agglutination. The S-LPS molecules carry the A and M antigens, which have different 
quantitative distribution among the smooth Brucella strains. This is of value in differentiating biovars of 
the major species using absorbed monospecific A and M antisera. Serological cross-reactions have been 
reported between smooth Brucellaand various other Gram negative bacteria, e.g. Escherichia coli O:116 
and O:157, Salmonella group N(O:30) of Kaufmann-White, Pseudomonas multophilia, Vibrio cholerae and 
especially Yersinia enterocolitica O:9. These organisms can induce significant levels of antibodies which 
cross-react with S-LPS Brucella antigens in diagnostic tests. 
1.4 TAXONOMY OF BRUCELLA SPECIES AND BIOVARS 
Considering their high degree of DNA homology (> 90 % for all species), Brucellae have been proposed as 
a monospecific genus in which all types should be regarded as biovars of B. melitensis (Verger et al., 
1985). Since this proposal has not yet met with complete agreement, the old classification of the genus (and 
relevant nomenclature) into six species, i.e. B. melitensis, B. abortus, B. suis, B. neotomaeae, B. ovis and B. 
canis (Corbel and Brinley Morgan, 1984), is the classification used world-wide. The first 4 species are 
normally observed in the smooth form, whereas B. ovis and B. canis have only been encountered in the 
rough form. Three biovars are recognised for B. melitensis (1-3), seven for B. abortus (1-6 and 9), and five 
for B. suis (1-5). 
Species identification is routinely based on lysis by phages and on somesimple biochemical tests (oxidase, 
urease). For B. melitensis, B. abortus and B. suis, the identification at the biovar level is currently 
performed byfour main tests, i.e. carbon dioxide (CO2) requirement, production of hydrogen sulphide 
(H2S), dye (thionin and basic fuchsin) sensitivity, and agglutination with monospecific A and M anti-sera 
(see Table 1). Moreover, a recently developed co-agglutination test, using latex beads coated with a pair of 
monoclonal antibodies directed against the rough lipopolysaccharide(R-LPS) and the 25 kDa outer 
membrane protein (Omp 25), respectively(Bowden et al., 1997), makes it possible to accurately 
differentiate B. ovis from B. canis and the occasional rough isolates of the smooth Brucella species B. 
melitensis biovar 3 appears to be the most frequently biovar isolated in Mediterranean countries. The 
precise recognition of biovar 3,especially its differentiation from biovar 2 appears sometimes equivocal. 
Due to the use of insufficiently discriminating monospecific sera, a number of strains identified initially as 
biovar 2 were later confirmed as biovar 3 by expert laboratories. 
Intermediate strains are occasionally found due to the instability reported for some of the phenotypic 
characteristics used for the current classification of Brucella. This situation sometimes impedes the 
identification of the species and their biovars. Therefore, the identification of stable DNA-specific markers 
is considered a high priority for taxonomic, diagnostic and epidemiological purposes. 
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Table 1. Biovar differentiation of Brucella species involved in sheep and goat brucellosis 
(SANCO.C.2/AH/R23/2001) 
Several methods, mainly PCR-RFLP and Southern blot analysis of variousgenes or loci, have been 
employed to find DNA polymorphism which wouldenable the molecular identification and typing of the 
Brucella species andtheir biovars (Allardet-Servent et al.,1988; Ficht et al.,1990, 1996; Halling and Zehr, 
1990; Halling et al.,1993; Fekete et al.,1992b; Ouahrani-Bettache et al., 1996; Vizcaino et al., 1997). 
Among thesemethods, detection of polymorphism by PCR-RFLP is considered to have an advantage over 
Southern blotting, since it is easier to perform and is lesstime-consuming when applied to large numbers of 
samples. 
 
2 THE DISEASE 
Pathogenically, B. melitensis infection in sheep and goats is similar to B. abortus infection in cattle. 
Nevertheless, differences are significant, and each species of Brucella causes a different disease (OIE 
Manual, 1996). Brucella are facultative intracellular parasites of the reticulo endothelial system. The 
virulence of Brucella varies considerably according to species, strain and the size of infecting inoculum. 
Host susceptibility is also variable and is associated with the reproductive status. Thus, in the field, all 
intermediate stages between typical acute infection and complete resistance may be observed. In addition, 
vaccinal immunity may modify the parasite-host relationship. 
Transmission within the hosts may occur via ingestion of Brucella contaminated feed or water or licking an 
infected placenta, calf or fetus, or the genitalia of an infected animal soon after it has aborted or gave birth 
(Alexander et al., 1981; Godfroid et al., 2004). As the bacterial concentrations in fetal fluids or placenta 
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after abortion can be as high as 109 to 1010 colony-forming units (CFUs)/g and minimum infectious doses 
are estimated in the 103 to 104 CFU range, abortion events can laterally transmit brucellosis to many cattle 
that have contact with birthing materials (Olsen and Tatum, 2010).Moreover, transmission within the 
natural hosts can occur through milk or via semen or genital secretions during mating. Zoonotic 
transmission occurs most frequently via unpasteurized milk products in urban settings, while occupational 
exposure of farmers, veterinarians, or laboratory workers can result from direct contact with infected 
animals or tissues or fluids associated with abortion (Olsen and Palmer, 2014). Only rare cases of vertical 
and horizontal (Wyatt, 2010) transmission between humans have been reported (Ruben et al., 1991; Mantur 
et al., 1996; Çelebi et al., 2007; Meltzer et al., 2010) and humans are generally considered to be incidental, 
or dead-end hosts for Brucella species (Meltzer et al., 2010). The spillover of brucellae from wildlife to 
domestic ruminants is also possible (Mick et al., 2014). 
2.1 PHASES OF INFECTION  
The infection in females follows a course very similar to B. abortus infection in cattle. The major route of 
infection appears to be through the mucous membranes of the oropharynx and upper respiratory tract or the 
conjunctiva. Other potential routes of infection are through the mucous membranes of the male or female 
genital tract. After gaining entrance to the body, the organisms encounter the cellular defences of the host, 
but generally succeed in arriving via the lymph channels at the nearest lymph node. The fate of invading 
bacteria is mainly determined by the cellular defences of the host, chiefly macrophages and T lymphocytes, 
though specific antibody undoubtedly plays a part. The outcome depends on the ruminant species infected, 
age, immune status of the host, pregnancy status, and the virulence and number of the invading Brucella. 
When the bacteria prevail over the body defences, a bacteraemia is generally established. This bacteraemia 
is detectable after 10 to 20 days and persists from 30 days to more than 2 months. If the animal is pregnant, 
bacteraemia often leads to the invasion of the uterus. At the same time, infection becomes established in 
various lymph nodes and organs, often in the udder and sometimes in the spleen. During this first stage of 
infection, the major clinical sign is abortion but other signs due to a localisation of Brucellamay be 
observed (ie, orchitis, epididymitis, hygroma, arthritis, metritis, subclinical mastitis, etc.). However, 
numerous animals develop self-limiting infections or they become asymptomatic latent carriers and 
potential excretors. Abortion generally does not occur if the female becomes infected at the end of 
pregnancy. The second stage is characterised by either elimination of Brucella or, more frequently, by a 
persistent infection of mammary glands and supramammary and genital lymph nodes (Fensterbank, 1987) 
with constant or intermittent shedding of the organisms in the milk and genital secretions. Animals 
generally abort once, during the mid third of gestation, but reinvasion of the uterus occurs in subsequent 
pregnancies with shedding in 18 fluids and membranes. The pregnancy can also continue to full-term. The 
proportion of newly infected females that abort varies with the circumstances. The percentage of infected 
females lambing/kidding in a flock may reach 40%. Females that are born into an infected environment and 
subsequently infected, generally abort less than others. This explains the high level of abortions in newly 
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infected flocks and their relatively low frequency in flocks where infection is enzootic. The udder is a very 
important predilection site for B. melitensis. Infection in lactating non-pregnant goats is likely to lead to 
colonisation of the udder with excretion of B. melitensisin the milk (Renoux et al., 1953). In goats, about 
two thirds of acute infections acquired naturally during pregnancy lead to infection of the udder and 
excretion of the bacteria in the milk during the subsequent lactation (Alton, 1985). In some goats excretion 
may cease during this lactation, but in many it persists and often continues during the next (Alton, 1962). 
Greatly reduced milk yield follows abortion, and infection of the udder following a normal birth also leads 
to a considerable reduction in yield. In spite of this, clinical signs of mastitis are seldom detectable in 
naturally infected goats (Alton, 1990). Sheep that abort often excrete the bacteria in the milk, but generally 
for not more than two months (Alton, 1990). However, exceptionally, excretion may continue for 140 days 
(Itabashi et al.,1938) and even 180 days (Biggi, 1956).  
2.2. IMMUNE RESPONSE 
Infection with Brucella usually results in the induction of both humoral and cell-mediated immune 
responses, but the magnitude and duration of these responses is affected by various factors including the 
virulence of the infecting strain, the size of infecting inoculum, pregnancy, sexual and immune status of the 
host (Joint FAO/WHO Expert Committee on Brucellosis, 1986) (Fig.1). 
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Fig.1 Simplified representation of immune response against 
Brucella (Skendros, Boura, 2013) Phagocytosis and/or pattern 
recognition receptor (e.g. TLR) signalling lead to the activation of APC and 
the priming of naïve CD4+ T lymphocytes towards a Th1 phenotype (innate 
immunity). The Th1 cytokines (TNFα, IFNγ) enhance the anti-Brucella 
mechanisms of macrophages (Mφ) and induce the CD8+CTL-mediated 
cytotoxicity against Brucella-infected Mφ (specifi c cellular immunity). 
Innate lymphocytes are early producers of IFNγ, linking innate to specific 
immunity. The Th2 response activates B lymphocytes (B) for antibody 
production, facilitating the phagocytosis of Brucella through opsonisation 
(specific humoral immunity). The Th2 cytokines (e.g. IL-10) inhibit the 
action of Th1 cytokines (e.g. IFNγ) and vice versa 
2.3 HUMORAL IMMUNITY  
Following infection by natural exposure, a serological response can be expected within 2 to 4 weeks, but 
the response is variable and may be absent altogether. Invasion of the pregnant uterus can be expected to 
produce a large and persistent rise of antibodies, but this may be delayed until after abortion or parturition 
at the normal time. Invasion of the lactating udder causes a lesser serological response, and localisation 
confined to a small number of lymph nodes may fail to stimulate any response at all, or only a minimal one. 
The pattern of the serological response in terms of immunoglobulin production has not been extensively 
studied in sheep and goats, but available information suggests close similarity to that in cattle, ie, 
production of IgM followed within a week or two by a predominance of IgG, with both isotypes falling to a 
low level in the more chronic stage of infection but with IgG predominating. The serological response is 
transient and sometimes missing in young sexually immature animals. As mentioned thereafter, the B. 
melitensis Rev.1 vaccine strain when applied under standard conditions (ie full dose via the subcutaneous 
route in young replacement animals) may induce a long lasting serological response to the agglutination 
test, that seriously interferes with serological screening for infected animals (Alton and Elberg, 1967; 
Elberg, 1981, 1996; Alton, 1990; MacMillan, 1990). As no differences have been found between the 
diagnostic antigens from field strains of B. melitensis and those from the Rev.1 vaccine, serological tests 
capable of distinguishing antibodies arising from infection and vaccination, respectively, have not been 
developed.  
2.4 CELL MEDIATED IMMUNITY  
Once the bacteria are phagocytosed by macrophages, DCs (Billard et al.,2007), and other antigen 
presenting cells (APCs),approximately 40–50% of the bacteria resist digestion within these cells. After 
initial encounter with Brucella antigens, APCs produce interleukin-1(IL-1),interleukin-6 (IL-6),tumor 
necrosis factor alpha (TNF-α), and gamma-interferon(IFN-γ) initiating innate immuneresponses (including 
natural killer cells) that may limit the initial spread of organisms. Infected APC in which organisms 
8 
 
residing with inunactivated phagolysosomes are likely to present some subset of peptidic Brucella antigens 
to CD4+ and CD8+ cells, and thus inducing a TH1 response associated with IFN-γ release. The functional 
consequences of antigen-specific IFN-γ release is unclear but does not lead to elimination of organisms 
during active, symptomatic infection and likely results in clinical symptomatology (i.e., fever, sweating, 
weightloss). Clonal T cell expansion is initiated with production of interleukin-2 (IL-2) and interleukin-12 
(IL-12), which initiates a CD8+ cytotoxic response on Brucella-infected cells. Infected macrophages 
produce IL-12 and IFN-γ which regulate antigen presentation and may contribute to the limitation of 
intracellular bacterial replication through unknown mechanisms (Akbulut et al.,2005). The protective 
immunity requires activated antigen-presenting cells (mainly macrophages and dendritic cells) as well as 
CD4+, CD8+ and γδ+ T-lymphocytes activation. Vitryet al demonstrated that CD4+ IFN-γ+ T cell subsets 
play a key role in containing Brucella infection (at least through in vitro infection) (Vitryet al, 2012) while 
Skendroset al demonstrated that γδ+ T cell are of great importance in containing the infection, since they 
produce IFN-γ+ and IL8 at different time post infection (Skendroset al, 2011).As mentioned above, after 
gaining entrance into the body, the organisms encounter the cellular defences of the host and the fate of 
invading bacteria is mainly determined by the cellular defences of the host, in particular macrophages and 
T lymphocytes. The most widely used correlates of CMI are lymphocyte stimulation, macrophage 
inhibition, delayed-type hypersensitivity and γ−interferon induction. Like the humoral response and 
depending on the method used to measure the cell mediated immunity the response can be expected as 
rapidly as a few weeks, but the response is variable and may not be detected.  
2.5 EVADING IMMUNE SYSTEM  
Many mechanisms contribute to allowing Brucellae to survive within the intracellular environment, and 
evade not only the innate immunity, but CD4+ -  and CD8 + - mediated host cell killing (Covert et 
al.,2009). As Brucella cannot multiply outside their mammalian hosts, the most important aspect of 
Brucella ecology is their ability to establish an intracellular replicative niche and remain protected from the 
host immune responses (Bargen et al., 2012). Brucellae lack classic virulence factors like toxins, fimbriae 
and capsules which raises the possibility that they might have unique and subtle mechanisms to penetrate 
host cells, elude host defenses, alter intracellular trafficking to avoid degradation and killing in lysosomes 
and modulate the intracellular environment to allow long-term intracellular survival and replication (Delrue 
et al., 2004). The Brucella LPS O-polysaccharide appears to be a key molecule for cellular entry, to 
prevent complement-mediated bacterial lysis and to prevent apoptosis (i.e. programmed cell death) of the 
macrophages within which they reside allowing them to extend their longevity (de Bagüés et al., 2004; 
Lapaque et al., 2005). Brucella has developed mechanisms to avoid innate immunity by minimizing 
stimulation of pattern recognition receptors (PRRs) of the host. The Brucella cell envelope has high 
hydrophobicity and its LPS has a non-canonical structure that elicits a reduced and delayed inflammatory 
response compared with other Gram-negative bacteria (Rittig et al., 2001) and has lower stimulatory 
activity on TLR4 receptors (Rittig et al., 2003). The O side chain on the LPS can form complexes with the 
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major histocompatibility complex class II molecules that interfere with the ability of macrophages to 
present exogenous proteins. Brucella ornithine-containing lipids and lipoproteins in the outer membrane are 
poor activators of innate immunity. The rough (vaccine) strains (i.e., strains with lipopolysaccharide 
lacking the O-side chain) are less virulent because of their inability to overcome the host defense system 
(Rittig et al., 2003). However, under in vitro conditions, up to 90% of virulent Brucella and 99% of 
nonvirulent Brucella may be killed following intracellular entry (Porte et al., 1999). 
2.6 SURVIVAL INSIDE HOST CELL  
After entering into the host cell, smooth Brucella quickly traffic through the early endosomal compartment 
and depart the phagosome to form the modified phagosome (termed brucellosome). Brucella initially 
localize within acidified phagosomes (Rittig et al., 2001), where they are exposed to free oxygen radicals 
generated by the respiratory burst of phagocytes. Brucellae have multiple mechanisms to detoxify free 
radicals. Brucella expresses 2 superoxide dismutases (SodA and SodC), which detoxify superoxide anions 
generated by the respiratory burst of phagocytes. Brucellae require acidification of the phagosomal 
compartment to a pH<4.5 before they display wild-type intracellular replication in initial stages of 
intracellular infection. Localization in an acidified environment induces expression of the VirB operon 
(virB 1–10), which controls expression of genes associated with a type IV secretion system. The VirB 
operon interacts with the endoplasmic reticulum to neutralize the pH of the phagosome (Anderson et al., 
2008). The Brucella-induced modifications of the phagosome prevent fusion with the lysosome. Virulent 
Brucella strains express a cyclic glucan synthase that produces and secretes low molecular weight cyclic 
glucans. These molecules disrupt the lipid raft microdomain structures within intracellular membranes 
surrounding the bacteria. This modification of lipid raft distribution in phagosomal membranes inhibits 
phagosome maturation, prevents fusion with lysosomes (ArellanoReynoso et al., 2005). 
2.7 SURVIVAL OUTSIDE HOST CELL  
Brucella may remain viable within the environment for a period of time. In general, the viability of 
Brucella spp. outside the mammalian host is enhanced by cool temperatures and moisture and decreased by 
high temperatures, dryness and direct exposure to sunlight. For example, B. abortus survives a couple of 
hours under direct sunlight but up to 185 days in the cold and shade. Brucella abortus also survives in 
aborted fetuses, manure and water for periods of up to 150 to 240 days (Saegerman et al., 2010). 
2.8 ZOONOTIC ASPECTS OF BRUCELLA INFECTIONS 
Human brucellosis is widely distributed all over the world, with regions of high endemicity such 
Mediterranean, Middle East, Latin America and parts of Asia (Corbel, 1997, López-Merino, 1989). The 
true incidence of human brucellosis is unknown. Reported incidence in endemic-disease areas varies 
widely, from 200 per 100,000 population (López-Merino, 1989). Humans are accidentally infected and 
almost always dead-end hosts of Brucella infections. The disease is primarily an occupational risk in 
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exposed professions, i.e. veterinarians, farmers, laboratory technicians, abattoir workers, and others who 
work with animals and their products. People living near infected premises may also contract infection. The 
primary source is the animal and infection is contracted either by direct or indirect contact through the skin 
or mucous membranes or ingestion of contaminated products, especially fresh dairy products. The 
maximum danger is therefore during the lambing or kidding period. Dairy products are the 8 main source 
of infection for people who do not have direct contact with animals. The prevalence of human brucellosis 
acquired from dairy products is seasonal, reaching a peak soon after kidding and lambing. Abattoir workers 
handling infected animals are also at risk, especially from the contents of uteri and udders. The handling of 
raw wool has been identified as a potential source of infection of workers involved. Finally, B. melitensis is 
easily acquired by laboratory infection. Humans are susceptible to B. abortus, B. melitensis, B. suis.B. 
melitensis and B. suisoften give rise to a severe and long lasting form of the disease. After an incubation 
period of 8 to 20 days, illness occurs in different forms. Asymptomatic infection is frequent and mainly due 
to B. abortus. It is characterised by antibody formation in persons with no history of symptoms consistent 
with brucellosis. The acute form of the disease is also common and symptoms include lassitude, headache 
and muscular or joint pain, and drenching sweats, especially at night. The manifestations of brucellosis are 
sometimes more pronounced or limited to a specific system or organ. This is then termed a complication 
when it occurs in the course of acute infection, or localised brucellosis when occurring in the absence of 
other signs of systemic illness. The most common localisations are spondylitis, peripheral arthritis, 
especially of the hip, knee and shoulder, or epididymo-orchitis. Nervous, genitourinary, hepatosplenic and 
cardiovascular complications may also be observed. Brucellosis is termed chronic when it includes one or 
more of the signs described above and persists or recurs over a period of six months or more. 
FinallyBrucella dermatitis has traditionally been ascribed to "allergy" to Brucella. Familiarity with the 
manifestations of brucellosis and knowledge of the optimal laboratory studies are essential for the 
recognition of this reemerging zoonosis.B melitensis, B abortus, and B suis have been completely 
sequenced, and these sequencing data will help improve our understanding of the pathogenesis and the 
manifestations of this complex disease. 
 
3. DIAGNOSTIC TESTS 
The disease presents a great variety of clinical manifestations, making it difficult to diagnose clinically. 
Therefore, the diagnosis must be confirmed directly by isolation of Brucella, mostly from blood culture, or 
indirectly by the detection of immune response against its antigens. Clinically, identification to the genus 
level is sufficient to warrant initiation of therapy. The particular Brucella  species involved does not affect 
the choice of therapeutic agents; however, speciation is necessary for epidemiologic surveillance and 
requires more detailed biochemical, metabolic, and immunologic testing. 
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The diagnosis of brucellosis based exclusively upon Brucella isolation presents several drawbacks (Orduña 
et al.,2000). The slow growth of Brucella in primary cultures means that diagnosis may take more than 7 
days (Ariza, 1996, Rodríguez-Torres HWDO., 1987, Yagupsky, 1999). Besides, blood culture sensitivity is 
often low, ranging from 50-90 % depending on disease stage, Brucella species, culture medium, number of 
circulating bacteria and the culture technique employed (Gotuzzo et al., 1986, Yagupsky, 1999). Hence, 
serological tests play a major role in diagnosis when the agent cannot be detected by blood culture. Yet, the 
interpretation of these tests is often difficult, particularly in patients with chronic brucellosis, in re-
infections and relapses, and in endemic areas where a high portion of the population carries antibodies 
against brucellosis (Orduña et al., 2000). Various serological tests have been used for the diagnosis of 
human brucellosis. The most common tests used are serum agglutination test (SAT), Coombs anti-Brucella 
test, Rose Bengal test and complement fixation test (Orduña et al., 2000). During 9 the last decade, 
radioimmunoassays (Hewitt and Payne, 1984, Parrat et al.,1977) and in particular enzyme-immunoassays 
(Ariza et al.,1992, Gazapo et al.,1989, Saz et al.,1987) have also been used. Other tests have proved useful 
in some patients, such as the indirect immunofluorescence test, Brucellin counter-electrophoresis and 
passive haemagglutination test, but their value in clinical practice is still under assessment. Allergic tests 
reveal a delayed-type hypersensitivity; using conventional antigen preparations. Brucellin-INRA, a S-LPS 
free product was reported as reliable and innocuous, but further work is necessary. 
3.1 DIRECT DIAGNOSIS: AGENT DETECTION 
3.1.1 ISOLATION OF BACTERIA 
The only unequivocal method for the diagnosis of brucellosis in smallruminants is based on the isolation of 
Brucella bacteria. (Altonet al.,1988).The presumptive bacteriological diagnosis of B. melitensiscan be 
made by means of the microscopic examination of smears from vaginal swabs,placentas or aborted foetuses 
stained with the Stamp modification of theZiehl-Neelsen method. However, morphologically related micro-
organisms such as B. ovis, Clamydia psittaci or Coxiella burnetiican mislead thediagnosis. Accordingly, 
the isolation of B. melitensis on appropriate culture media is recommended for an accurate diagnosis. 
Vaginal swabs and milk samples are the best samples to isolate B. melitensis from sheep and goats.The 
spleen and lymph nodes (iliac, mammary and prefemoral) are the most reliable samples for isolation 
purposes in necropsied animals (Marín et al.,1996a). B. melitensis does not require serum or CO2 for 
growth and can be isolated on ordinary solid media under aerobic conditions at 37°C. However, the useof 
nonselective media cannot be recommended because of the over growing contaminants usually present in 
field samples, and selective media are needed for isolation purposes. The Farrell’s selective medium, 
developed for the isolation of B. abortus from milk (Farrell, 1974), is also recommended for the isolation of 
B. melitensis (Alton et al.,1988). However, nalidixic acid and bacitracin, at the concentration used in this 
medium, may have inhibitory effects on some B. melitensis strains (Marín et al.,1996b). Thus, its 
sensitivity for the isolation of B. melitensis from naturally infected sheep is sometimes lower than that 
obtained with the less selective Thayer-Martin’s modified medium (Marín et al.,1996a). The sensitivity of 
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bacteriological diagnosis is significantly increased by the simultaneous use of both the Farrell’s and the 
modified Thayer-Martin’s media (Marín et al.,1996b).Additional work should be carried out to develop a 
new selective medium that is more efficient and suitable for isolating all Brucella species. 
3.1.2 OTHER METHODS FOR AGENT DETECTION 
While culturing is a specific method, its sensitivity depends on the viabilityand numbers of Brucellawithin 
the sample, the nature of sample (foetal organs, foetal membranes, lymph nodes, etc.) and the number of 
specimens tested from the same animal (Hornitzky and Searson, 1986). The time required for culturing 
field specimens can be long and tissues or fluids that are only contaminated with a low number of 
Brucellamay not be detected. Thus, in the case of tissues or fluids contaminated with non viable or a 
lownumber of Brucella, PCR could be a potentially useful method for the diagnosis of brucellosis. Several 
authors reported a good sensitivity of PCR for detecting of Brucella DNA on pure cultures (Fekete et al., 
1990a, 1990b). Others showed that PCR could be a potentially useful tool when used alone (PCR, AP-PCR, 
rep-PCR, ERIC-PCR) or in combination with labelled probes to differentiate some Brucella species and 
biovars (Fekete et al., 1992b, Bricker and Halling, 1994, Tcherneva et al., 1996). The possibility of PCR 
techniques to detect the DNA of dead bacteria, or in paucibacillary samples and even in samples highly 
contaminated with other micro-organisms, could potentially increase the rate of detecting animals infected 
with Brucella. However few studies have been performed with clinical or field samples (Fekete et 
al.,1992a; Rijpens et al., 1996)and up to now, no technique has been demonstrated to be sensitive enough 
to replace classical bacteriology on all kinds of biological samples. 
3.2 INDIRECT DIAGNOSIS: ANTIGEN OF BRUCELLA AND ANTIGEN DECTECTION 
There is no scientific agreement on what should be the nature andcharacteristics of a universal 
antigen for diagnosing brucellosis due to smooth Brucella (B. abortus, B. melitensis and B. suis). 
One of the most controversial points concerning the serological diagnosis of B. melitensisinfection 
in small ruminants is related to which Brucella species and biovarsare used in the production of 
the diagnostic antigens. The rose bengal test (RB) and the complement fixation test (CF) are the 
most widely used tests for the serological diagnosis of sheep brucellosis (Farina, 1985; 
MacMillan,1990). They are currently the official tests used in member states of theEuropean 
Union (Council Directive 91/68/EEC). The antigen suspensions(whole cells) used in both tests are 
made with B. abortus biovar 1 (an Adominant strain) (Alton et al.,1988) which means that, 
theoretically, infections due to M-dominant strains B. melitensis biovar 1; B. abortus biovars 4, 5 
and 9; B. suis biovar 5) could be misdiagnosed (Alton et al.,1988; MacMillan, 1990). However, 
recent results showed that the sensitivity of the classical RB antigen prepared with B. abortus 
biovar 1 (A-dominant)was adequate for diagnosing ovine populations infected with the M 
dominantB. Melitensis biovar 1 (Blasco et al.,1994b). 
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The outer membrane of the bacteria contains the main antigens involved in the humoral response 
against Brucella (Díaz et al.,1968a). As in other gram negative bacteria, the outer membrane of 
smooth Brucella is composed of phospholipids, proteins and LPS (smooth lipopolysaccharide, S-
LPS). The S-LPS is the immunodominant antigen. Most serological tests, particularly those using 
whole-cell suspensions as antigen (such as RB, CF), as well as ELISA , have been developed to 
detect antibodies to this antigen (Díaz et al.,1968a). The S-LPS of smooth Brucella is composed 
of an inner glycolipidic moiety (the core oligosaccharide plus the lipid A) and an outer 
polysaccharide chain (O-chain). This O-chain is the relevant antigenic moiety and is chemically 
composed of a perosamin homopolymer showing α-1,2 and α-1,3 linkages (Cherwonogrodzky et 
al.,1990). The O-chain polysaccharide of B. abortus biovar 1 (A dominant) possesses a fine 
structure with only a low-frequency (ca.2%) of α-1,3 linked 4,6 dideoxy-4-formamido-D-
mannopyranoside residues. In contrast, the O-chain polysaccharide of B. melitensisbiovar1 (M-
dominant) contains repeated pentasaccharide units with one α-1,3 and four α-1,2 linkages. As a 
result, the A and M antigenic characteristics depend on the O- polysaccharides in which the 
frequency of α-1,3 linked residues varies. Studies with monoclonal 
antibodies (Douglas and Palmer, 1988) have shown that the A epitope is related to portions of at 
least five sugars with α-1,2 linkages and that the M epitope includes sugars with α-1,3 linkages 
(thus its relevance in the O-chain of B. abortusbiovar1 should not be important). Therefore, all 
biovars assigned as A-dominant should express few or no α-1,3 linked residues, while M-
dominant strains possess a unique M epitope as well as a di-, tri- or tetrasaccharide with α-1,2 
linkages, and can thus be considered to be contained within the A epitope structure(Bundle et 
al.,1989; Meikle et al.,1989; Cherwonogrodzky et al.,1990). The presence of common 
oligosaccharides of four or less sugars is consistent with the existence of a common (C) epitope. 
Indeed, this C epitope has been detected with the appropriate monoclonal antibodies (Douglas and 
Palmer, 1988) and can account for the high sensitivity of the antigens made from A-dominant 
strains (ie B. abortusbiovar 1) at detecting M-dominant B. melitensisbiovar 1 infections and vice-
versa (MacMillan, 1990; Díaz-Aparicio et al.,1993). In fact, crude LPS extracts from either B. 
melitensis 16M (biovar 1, M-dominant) or B. abortus2308 (biovar 1, A-dominant) are equally 
sensitive in an indirect ELISA (i-ELISA) for diagnosing brucellosis in sheep infected by B. 
melitensis biovar 1. However, the native hapten and the S-LPS hydrolytic polysaccharides 
containing the O-chain and core sugars from B. abortus biovar 1 failed to react in precipitation 
tests with a large proportion of B. melitensis infected sheep, goats and cattle under conditions in 
which the same antigens obtained from B. melitensis biovar 1 detected most of those animals 
(Díaz-Aparicio et al.,1993). Therefore, further research is needed to clarify the practical 
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importance and interest of using species-specific diagnostic antigens for the different serological 
tests. 
There is limited information on the value of outer membrane and innercytoplasmic proteins for the 
diagnosis of Brucella infection in sheep. 
The immunoelectrophoretical patterns of cytoplasmic proteins show little differences between 
Brucella species when assayed with polyclonal sera (Díaz et al.,1967, 1968b). These inner 
antigens are considered specific for the genus, being useful to differentiate infections due to 
Brucella from those due to bacteria whose LPS cross-reacts with the Brucella S-LPS, as is the 
case with Yersinia enterocoliticaO:9. However, a cross-reactivity among cytosolic proteins of B. 
melitensis and those obtained from Ochrobatrum anthropi, an opportunistic human pathogen, has 
been reported recently (Velasco et al.1997). The Brucella cytoplasmic antigens have been used 
successfully for the allergic diagnosis of brucellosis in sheep and goats (Blasco et al.,1994b). 
Moreover, these cytoplasmic antigens have been reported to be sensitive and specific enough for 
the diagnosis of brucellosis in sheep and goats when used in precipitation tests (Díaz-Aparicio et 
al., 1994). In contrast, when these cytoplasmic antigens are used in the i-ELISA, the sensitivity 
obtained is not adequate due to the high background IgG reactivities with sera from Brucella free 
animals (Díaz-Aparicio et al., 1994). An important drawback of diagnostic test susing 
uncharacterised cytosolic proteins is the lack of specificity when testing Rev.1 vaccinated sheep 
and goats. But a partially purified cytosoluble protein of 28 kDa (CP28) from the cytosoluble 
protein extract (CPE) of B. melitensis has been reported as being able to differentiate Rev.1 
vaccinated from B. melitensis infected ewes when used in i-ELISA (Debbarh et al.,1995). 
However, this test is less sensitive than both the RB and CF tests for diagnosing B. melitensis 
infected ewes. The corresponding B. melitensis16M bp26gene was expressed in Escherichia coli 
and monoclonal antibodies were produced (Cloeckaert et al., 1996a). Sequence analysis of the 
cloned gene revealed that it was nearly identical to the recently published B. abortus bp26gene, 
coding for a periplasmic protein (Rossetti et al., 1996). A competitive ELISA (c-ELISA)using 
CPE as antigen and some of these monoclonal antibodies showed improved sensitivity for 
diagnosing infected sheep, and no antibody response was detected in Rev.1 vaccinated sheep 
(Debbarh et al., 1996). 
Several authors have attempted to identify the main polypeptide specificities of the antibody 
response to outer-membrane protein (OMP) extracts of B. melitensis by using either 
immunoblotting or c-ELISAs with specific monoclonal antibodies (Tibor et al., 1996). While 
OMPs of 10, 17, 19, 25-27and 31-34 kDa were found as potential antigens for the diagnosis of 
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brucellosis in sheep by immunoblotting or ELISA, the antibody response to them was very low 
and heterogeneous in B. melitensis infected sheep(Zygmunt et al., 1994a). 
 
3.3. SEROLOGICAL TESTS 
Considering that infections by B. abortus and B. melitensis cause two different diseases in any of the 
susceptible host species, it is striking that no specific serological tests for B. melitensis infection of sheep 
have been developed. Instead, it is widely assumed that the serological tests used for B. abortus infection in 
cattle are also adequate for the diagnosis of B. melitensis infection in small ruminants. Accordingly, the RB 
and CF test are the most widely used tests for the serological diagnosis of brucellosis in sheep and goats 
(Farina, 1985; Alton, 1990; MacMillan, 1990). There is a considerable body of knowledge available on the 
diagnostic value of tests such as iELISA, cELISA, FPA, Coombs test or immunocapture test for ruminants 
in general. However, such knowledge does not enable to make a clear choice regarding the selection of a 
test for use in the serodiagnosis of ovine and caprine brucellosis (OIE Manual, 2000). Occurrence of false-
positive serological reactions in surveillance and diagnostic testing for animal brucellosis is an important 
problem. Most commonly they are caused by infections with Yersinia enterocolitica serotype O:9 (YeO: 9), 
as this bacterium possesses an almost identical O-antigen LPS chain to that of Brucella abortus. Brucella 
LPS contain Brucella spp. specific M- and C-epitopes, as well as common A- or C/Y-epitopes that are 
shared with Ye O: 9, and a number monoclonal antibodies (mAbs) specifically recognizing these epitopes 
have been produced. However, although the exact structures of the various epitopes remain unclear, it 
appears that LPS epitopes span 2–5 overlapping polysaccharide units and that antibodies generated against 
the common A- or C/Y-epitopes are able to block the specific binding to adjacent M- and C-epitopes in 
competitive ELISAs. This means that antibodies generated by an infection with YeO:9 will also inhibit 
binding of Brucella-specific mAbs in diagnostic competitive ELISAs. Attempts to overcome the LPS cross 
reactions with the use of Brucella protein antigens is hampered by the strong humoral immune dominance 
of smooth LPS in Brucella infections. This is an area of continued research and new candidates for antigen 
preparations continue to be evaluated. Attempts to produce phage-displayed peptide mimotopes of the 
Brucella-specific LPS epitopes have not been successful when used in vaccines or indirect ELISAs. 
Diagnostic use of cellular mediated immune responses to discriminate these two infections is a potential 
alternative to serological assays. This approach has been successful in cattle (Blasco et al.,1994b). 
 
4.THESIS OBJECTIVES 
4.1 PRELIMINARY DATA 
To overcome the limitations of serological diagnosis, including false positive reactions caused by other 
pathogens, specific antigens for diagnosis of brucellosis other than those LPS-based are required. These 
antigens shouldn’t show any cross-reaction with whole of Yersinia enterocoliticaO:9, Vibrio cholerae, 
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Salmonella typhimurium, and Escherichia coli O157. Several study were published on the use of 
alternative immunogenic proteins of Brucella genus to minimize cross reactions in brucellosis diagnosis, 
but so far none of these have produced any good outcome. Therefore, attempts to find a protein antigen for 
differentiating Brucella-infected from cross-reactive animals remain the principal aim of many studies.  
Several authors have indeed demonstrated that the Brucella polysaccharide ‘O’ chain shares common 
features with various other bacteria (Nielsen et al., 2004; Muñoz et al, 2005). The relative lack of 
specificity and sensitivity of this test has often been presented as a major drawback for the diagnosis of 
brucellosis in cattle (Koet al., 2012). These factors bring up the need to develop new diagnostic methods 
able to distinguish between Brucella and other bacteria, in order to avoid worthless animal sacrifices. An 
independent confirmatory assay built on a non-LPS antigen and not expressed by an effective vaccine 
would be extremely useful. 
Many potentially diagnostically useful protein antigens have been reported, too many to list here, but some 
examples are Lumazine synthase , copper/zinc superoxide dismutase (Cu/Zn SOD) L7/L12 , and malate 
dehydrogenase . Perhaps the most frequently cited is BP26 – also known as outer membrane protein 
(OMP)28 (Pappas et al.,2006). The Broad Institute has recently sequenced 25 Brucella genomes, wich 
along with the pre-existing genomes provide a sequence from every biovar, as well as other isolates of 
veterinary interest (http://www.broadinstitute.org/annotation/genoma/brucella_group/MultiHome.html). In 
addition, three new genomes were recently sequenced by The Centre of Disease Control and annotated by 
PATRIC (Snyder et al., 2007). Looking at the genomic differences between Brucella and the other 
pathogens there are small differences that are of potential interest to obtain an hypothetical immunogenic 
and high specific protein. These discriminating sequences could be synthesized in vitro and then used to 
test their ability to stimulate the immune system to produce specific cytokines that could be used for 
differential diagnosis of brucellosis. Vitry et al demonstrated that CD4+ IFN-γ+ T cell subsets play a key 
role in containing Brucella infection (at least through in vitro infection) (Vitry et al , 2012) while Skendros 
et al demonstrated that γδ+ T cell are of great importance in containing the infection, since they produce 
IFN-γ+ and IL8 at different time post infection (Skendros et al, 2011).  
After a thorough review of the literature, objectives for the investigation of immune response and 
immunogenic proteins, in order to find a Brucella specific non-LPS protein(s) able to activate characteristic 
Brucella CD4+ and CD8+IFN-γ+lymphocytes were drawn up. 
Objective I: Bioinformatic studies. In order to set up a specific diagnosis to discriminate against Brucella 
infection from other diseases we carried out bioinformatic study of several identified non-LPS Brucella 
proteins. These included both genetic and immunological characterization of non-LPS immunogenic 
candidate antigens of Brucella in order to characterize their sequences and immune features, and to select 
the best non cross-reactive non-LPS epitopes, to employ during experimental infections, in order to provide 
important information for developing new diagnostic tools. 
17 
 
Objective II: Experimental infections in cattle 
The research aimed to study the IFN-γ+ T cell subsets during natural Brucella infection and experimental 
Yersinia immunization, in order to evaluate the potential diagnostic use of cell-mediated immune response 
to distinguish Brucella from Yersinia infections in cattle. We studied the release of cytokines from PBMCs 
(Peripheral Blood Mononuclear Cells)  collected from infected animals, after stimulation with Brucella 
antigens. The cytokines were detected in cell culture supernatants by using both an enzyme immunoassay 
method and cytofluorimetric analysis. The novelty of the approach is represented by the effort to detect the 
IFN-γ+ T cell subsets during natural Brucella infection and experimental Yersinia immunization after in 
vitro re-exposure with specific antigens. This approach was designed to evaluate the potential diagnostic 
use of these parameters to discriminate between the two infections. The results allowed to deepen 
knowledge on interaction between Brucella specific antigens and host immune cells and the identification 
of a specific cytokine pathway for differential diagnosis of brucellosis. 
 
5. MATERIALS AND METHODS 
5.1 BACTERIAL STRAIN SEQUENCE ANALYSIS 
 
Genotypic identification of the bacterial strains was carried out by 16S rRNA gene sequencing (Weisburg 
et al., 1991). Brucella and Yersinia cultures were grown on TSA plates. Extraction of genomic DNA was 
accomplished using the QIAamp DNA Mini Kit (Qiagen,Valencia, CA). The strains were genetically 
identified by 16S rRNA gene sequencing using the primers rD1 (5′  AAGGAGGTGATCCAGCC-3′) and 
fD1 (5′-AGAGTTTGATCCTGGCTCAG-3′) and the AmpliTaq Gold® 360 DNA Polymerase (Life 
Technologies, Carlsbad, CA, USA). DNA sequences were determinated by using an ABI PRISM 3130 
Genetic Analyzer (Applied Biosystems, Carlsbad, CA, USA). The sequences were compared with those 
available in the GenBank/EMBL/DDBJ (http://www.ncbi.nlm.nih.gov) (Altschul et al., 1997) databases. 
The last database compares a given sequence to those of type strains only. The isolates were considered to 
represent the species in question if 97% or higher similarity was detected (Stackebrandt and Goebel, 1994). 
The bacterial strains identified were employed to perform experimental infection in cattle and the future 
mouse models. 
5.2 PROTEIN BIOINFORMATICS STUDIES 
 
The bioinformatic study was carried out on several identified non-LPS Brucella proteins characterizing 
their sequences. The proteins selected were characterized for their amino acid sequences from PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) shown below: 
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PROTEIN  ACCESSION 
NUMBER 
AMINO ACID SEQUENCE 
ISOCITRATE 
LYASE  
 
>gi|492965089|ref|
WP_006071281.1| 
 
MTDFYSLIPSAPKGRFDGIERAHTAEDVKRLRGSVEIKYSLAEM
GANRLWKLIHEEDFVNALGALSGNQAMQMVRAGLKAIYLSGW
QVAADANTASAMYPDQSLYPANAGPELAKRINRTLQRADQIET
AEGKGLSVDTWFAPIVADAEAGFGGPLNAFEIMKAYIEAGAAG
VHFEDQLASEKKCGHLGGKVLIPTAAHIRNLNAARLAADVMGT
PTLIVARTDAEAAKLLTSDIDERDQPFVDYEAGRTAEGFYQVKN
GIEPCIARAIAYAPYCDLIWMETSKPDLAQARRFAEAVHKAHPG
KLLAYNCSPSFNWKKNLDDATIAKFQCELGAMGYKFQFITLAG
FHQLNYGMFELARGYKDRQMAAYSELQQAEFAAEADGYTAT
KHQREVGTGYFDAVSLAITGSQSSTTAMKESTETAQFKPAAE 
 
ENOYL-COA 
HYDRATASE  
 
>gi|489056931|ref|
WP_002967057.1|  
 
MNDFETLHIAVDHRGVARLTLNRPEQHNALSGRMIDELTTAAL
HLADNEAVRIVILTGAGTSFCAGGDLGWMREQVNATRAQRIEE
ARKLALMLKALRDLPKPLIGRINGQAYGGGVGLISVCDAAISIS
GARFGLTETKLGLIPATISPYVVARIGEANALRTFTSARLFDAEE
GRRIGLLHDVVEAERLDAAVEAEIKPYFSTAPAAVAASKRLVH
ALGAPIDEAVIDMTLTRLADTWETPEAAEGIAAFFAKRAPAWK
GGD 
 
SUGAR 
BINDING 
PERIPLASMIC 
PROTEIN 
 
>gi|38258624|sp|Q8
YCE2.2|SP39_ 
 
MHKLLKLAAMGTAACALLAGMAPVANAQEKQNVEVLHWWT
SGGEASALEVLKKDLESKGISWTDMPVAGGGGTEAMTVLRAR
VTAGNAPTAVQMLGFDIRDWAEQGALGNLDTVASKEGWEKVI
PAPLQEFAKYDGHWIAAPVNIHSTNWMWINKAALDKAGGKEP
TNWDELIALLDNFKAQGITPIAHGGQPWQDATIFDAVVLSFGPD
FYKKAFIDLDPEALGSDTMKQAFDRMSKLRTYVDDNFSGRDW
NLASAMVIEGKAGVQFMGDWAKGEFLKAGKKPGEDFVCMRY
PGTQGAVTFNSDMFAMFKVSEDKVPAQLEMASAIESPAFQSAF
NVVKGSAPARTDVPDTAFDACGKKAIADVKEANSKGTLLGSM
AHGYANPAAVKNAIYDVVTRQFNGQLSSEDAVKELVVAVEAA
K 
 
COML,COMPET
ENCE 
LIPOPROTEIN 
 
>gi|81852175|sp|Q8
YI58|Q8YI58_ 
 
MRSAKSTCCFKRERRYQRAGDRMTSFKFTGVTKTALLSGTIAV
LIPLAGCASKNDDIDLTKYVETIDPADKLYNEGLANLDAGRLDE
AAKKFAAIDRQHPYTEWARKALVMAAFTNYRKGNYEEAISMA
KRYNTLYPTSPESAYAYYIIGLSYFRQIPDVTRDQAASRRAIAAM
QEVIDRFPNSEYTDDAKTKIRVARDQLAGKEMQIGRYYLERKE
YLAAIKRFRGVVEEYSNTRQVEEALARLVEAYYALGLTSEAQM
AASVLGKNFPDSQWYKDSYKLLQSGGLQPRENGNSWLAKAGA
LITGGSS 
 
PERIPLASMIC 
DIPEPTIDE 
TRANSPORT 
PROTEIN 
>gi|81852305|sp|
Q8YIL0|Q8YIL0 
 
MDDKYDPEAAKKALEAAGVKDLSMKIWAMPVSRPYMPNARR
TAELMQADLAKVGVKADIVSMEWGKYLKKSSEKDRDGAVIM
GWTGDNGDPDNFLGTLLGCAGLGNNNRAQWCYKPFEDLIQKA
KTSTSQEERTKLYEEAQAVFKEQAPWDTIAHSTVFVPMSAKVT
GFKQSPLGDYRFEEVDISE 
 
MOLECULAR 
CHAPERONED
NAK  
 
>gi|493164348|ref|
WP_006170012.1| 
 
MAKVIGIDLGTTNSCVAVMDGKNAKVIENAEGARTTPSIIAFTD
GDERLAGQPAKRQAVTNPEGTLFAVKRLIGRRYDDPMVTKDK
DLVPYKIVKGDNGDAWVEVHGKKYSPSQISAMILQKMKETAES
YLGETVTQAVITVPAYFNDAQRQATKDAGKIAGLEVLRIINEPT
AAALAYGLDKSEGKTIAVYDLGGGTFDVSVLEIGDGVFEVKST
NGDTFLGGEDFDIRLVEYLVAEFKKESDIDLKNDKLALQRLKEA
AEKAKIELSSSQQTEINLPFITADQTGPKHLAIKLSRAKFESLVDD
LVQRTVEPCKAALKDAGLKAGEIDEVVLVGGMTRMPKIQEVV
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KAFFGKEPHKGVNPDEVVAMGAAIQGGVLQGDVKDVLLLDVT
PLSLGIETLGGVFTRLIERNTTIPTKKSQTFSTAEDNQSAVTIRVF
QGEREMAADNKLLGQFDLVGIPPAPRGVPQIEVTFDIDANGIVN
VSAKDKGTGKEHQIRIQASGGLSDADIEKMVKDAEANAEADKK
RRESVEAKNQAESLVHSTEKSLAEYGDKVSADDKKAIEDAIAA
LKTSLEGEDAEDIKAKTQALAEVSMKLGQAMYEAAAAEGAGA
EGGEQASSSKDDVVDADYEEIDDNKKSS 
 
CATALASE  
 
>gi|493053174|ref
|WP_006112539.
1|  
 
MTDRPIMTTSAGAPIPDNQNSLTAGERGPILMQDYQLIEKLSHQ
NRERIPERAVHAKGWGAYGTLTITGDISRYTKAKVLQPGAQTP
MLARFSTVAGELGAADAERDVRGFALKFYTQEGNWDLVGNNT
PVFFVRDPLKFPDFIHTQKRHPRTHLRSATAMWDFWSLSPESLH
QVTILMSDRGLPTDVRHINGYGSHTYSFWNDAGERYWVKFHF
KTMQGHKHWTNAEAEQVIGRTRESTQEDLFSAIENGEFPKWKV
QVQIMPELDADKTPYNPFDLTKVWPHADYPPIDIGVMELNRNP
ENYFTEVENAAFSPSNIVPGIGFSPDKMLQARIFSYADAHRHRLG
THYESIPVNQPKCPVHHYHRDGQMNVYGGIKTGNPDAYYEPNS
FNGPVEQPSAKEPPLCISGNADRYNHRIGNDDYSQPRALFNLFD
AAQKQRLFSNIAAAMKGVPGFIVERQLGHFKLIHPEYEAGVRK
ALKDAHGYDANTIA 
 
RIBOSE 
TRANSPORT 
SYSTEM 
SUBSTRATE-
BINDING 
PROTEIN  
>gi|496220735|ref
|WP_008934772.
1|  
 
MFKKGMRVLFAAAAALPLIASTAWAEGLMTIIVNDPSNPYWFT
EGEVAKKTAEGLGYKAVVGGHKGDTNTESNLIDTAITNKSVAII
LDPANADGSVGAVKRAIAANIPVFLINAEINQEGLAKAQLVSNN
AQGAALGATQWVESVGDKGKYVELFGAPSDNNAATRSNGYET
VLSQYPDLVRVGKDVANWDRT 
 
GLUTAMINE 
AMIDO 
TRANSFERAS
E  
>gi|490822964|ref
|WP_004685054.
1|  
 
MPSTRRIFMPIRTIVWGENIHEQINETVRSIYPEGMHNTIAGALN
EDGAIEATTATLQEPEHGLLTERLAQTDVLVWWGHKDHGGVS
DDVVERVARRVFEGMGLIVLHSGHFSKIFKRLMGTPCALKWRE
AGERVWVVNRGHPIAQGLEETFVLENEEMYGEQFSVPEPLETV
FISWFAGGEVFRSGMTWRRGAGNVFYFRPGHETYPTYHDANV
RTVLRNAVKWAYNPQPAWTGIHTAPNVPVEKALEPIVERGPKL
HKAGEAGYR 
 
SN-
GLYCEROL-3-
PHOSPHATE-
BINDING 
PERIPLASMIC 
PROTEIN 
UGPB  
>gi|493105393|ref
|WP_006138486.
1|  
 
MFTRLITTSALTGAIALTIGSQAFAQTELAWWHGMTGANNEMV
NELSKEFNESQSEYKIVPVYKGNYPETLNAGIAAFRSKQPPAILQ
VFDAGSGVMMAAEGAIVPAAEVLEKGGYKFDKSQYLPGIVAY
YSKPDGTMLSFPYNSSSPILYYNKDAFKKAGLDENKPPKTWPEV
FEAAKKIKASGASPCGFTST 
 
 
The blastp alignment tool (protein-protein BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) 
was used to detect the matching scores between Brucella protein and the corresponding Yersinia one. 
The proteins selected were characterized for their immune features, in order to find  B- and/or T-cell 
epitopes to be used as potential stimuli. We used specific tools able to predict IC50 values for peptides 
binding to specific MHC molecules (http://tools.immuneepitope.org/main/html/tcell_tools.html),antibody 
epitope ( http://tools.immuneepitope.org/tools/bcell/iedb_input), to detect the presence of transmembrane 
regions (TM) (http://www.cbs.dtu.dk/services/TMHMM/) and the presence of signal peptide (SP) 
(http://www.cbs.dtu.dk/services/SignalP/),  
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5.3 EXPERIMENTAL INFECTIONS IN CATTLE 
Blood samples were collected from three groups of cattle (N=5 for each group) experimentally immunized 
with Yersinia enterocolitica O:9 (Ye O:9) (Charolaise breed, 6-8 months old), naturally infected with B. 
abortus (confirmed by positivity to the official serological tests) (Holstein breed, 2-5 years old), and from 
officially Brucellosis free farms (as serological negative controls). PBMC were isolated from heparinized 
blood samples (La Manna et al., 2011) and in vitro stimulated with Yersinia enterocolitica O:9 (Yersinia 
enterocolitica O:9 YOP® - InstitutVirion/Serion GmbH, Germany - 80 µg/ml) and B. abortuswhole 
antigens (Brucellergene, OCB®Synbiotics, Kansas City, MO US - 80 µg/ml) alternatively. 5 x 105 
PBMC/well  were cultured for 48 h andthen collected. For cell acquisition and flow cytometry analysis a 
FACScan cytometer (Becton Dickinson, U.S.A.) was used, by staining the cells with anti-surface-FITC-
labeled and anti-IFN-γ PE-labeled mAbs. Surface immunofluorescence was detected by incubation of cells 
with anti-CD8 (FITC-labeled) anti-CD4 (FITC–labeled) and anti-WC1 (FITC-labeled) at 4°C. After three 
washes, the cells were fixed and permeabilized by Leucoperm™ reagent set (AbDSerotec, U.K.) and then 
incubated with anti-IFN-γmAb PE-labeled for 30 minutes at 4°C. After three washes, the lymphocytes were 
analyzed using a FACScan cytometer (Becton Dickinson, U.S.A.) using CELL-QUEST PRO software 
(Becton Dickinson, U.S.A.). Each analysis was performed collecting 10.000 events of live lymphocytes. 
The cells were gated according to their physical appearance using the forward scatter (FSC) and side scatter 
(SSC) parameters, to exclude debris and apoptotic cells.  
 
6.RESULTS AND CONCLUSIONS 
6.1. NUCLEOTIDE SEQUENCE BLAST RESULTS 
Brucella and Yersinia strain sequences compared using the BLAST search gave the following nucleotide 
sequence and alignment results: 
 
NULEOTIDE SEQUENCE BLAST RESULT 
TGGATTGACGTTACTCGCAGAAGAAGCACCGGCTAACTCCGTGCCA
GCAGCCGCGGTAATACGGAGGGTGCAAGCGTTAATCGGAATTACT
GGGCGTAAAGCGCACGCAGGCGGTTTGTTAAGTCAGATGTGAAATC
CCCGCGCTTAACGTGGGNACNGCATTTGAAACTGGCAAGCTAGAGT
CTTGTAGAGGGGGGTAGAATTCCAGGTGTAGCGGTGAAATGCGTA
GAGATCTGNAGGAATACCGGTGGCGAAGGCGGCCCCCTGGACAAA
GACTGACGCTCAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAGA
TACCCTGGTAGTCCACGCTGTAAACGATGTCGACTTGGAGGTTGTG
CCCTTGAGGCGTGGCTTCCGGAGCTAACGCGTTAAGTCGACCGCCT
GGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTNNCGGGGG
CCNGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGCAACGCGAA
GAACCTTACCTACTCTTGACATCCACGGAATTTAGCAGAGATGCTT
TAGTGNCTTCGGGAACCGTGAGACAGGTGCTGCATGGCTGTCGTCA
GCTCGTGTTGTGAAATGTTGGGTTAAGTCCCGCAACGAGCGCAACC
CTTATCCTTTGTTGCCAGCACGTAATGGTGGGAACTCAAAGGAGAC
TGCCGGTGATAAACCGGAGGAAGGTGGGGATGACGTCAAGTCATC
ATGGCCCTTACGAGTAGGGCTACACACGTGCTACAATGGCAGATAC
AAAGTGAAGCGAACTCGCGAGA 
>gi|176358|gb|M59292.1|YEPRR16SA 
Yersinia enterocolitica 16S ribosomal 
RNA (99%) 
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GTGTAGAGGTGAAATTCGTAGATATTCGGAGGAACACCAGTGGCG
AAGGCGGCTCACTGGACCATTACTGACGCTGAGGTGCGAAAGCGT
GGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAAC
GATGAATGTTAGCCGTCGGGGTGTTTACACTTCGGTGGCGCAGCTA
ACGCATTAAACATTCCGCCTGGGGAGTACGGTCGCAAGATTAAAAC
TCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGT
TTAATTCGAAGCAACGCGCAGAACCTTACCAGCCCTTGACATCCCG
GTCGCGGTTAGTGGAGACACTATCCTTCAGTTAGGCTGGACCGGAG
ACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGG
TTAAGTCCCGCAACGAGCGCAACCCTCGCCCTTAGTTGCCAGCATT
CAGTTGGGCACTCTAAGGGGACTGCCGGTGATAAGCCGAGAGGAA
GGTGGGGATGACGTCAAGTCCTCATGGCCCTTACGGGCTGGGCTAC
ACACGTGCTACAATGGTGGTGACAGTGGGCAGCGAGCACGCGAGT
GTGAGCTAATCTCCAAAAGCCATCTCAGTTCGGATTGCACTCTGCA
ACTCGAGTGCATGAAGTTGGAATCGCTAGTAATCGCGGATCAGCAT
GCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACA
CCATGGGAGTTGGTTTTACCCGAAGGCGCTGTGCTAACCGCAAGGA
GGCAGGCGACCACGGTAGGGTCAGCGACTGGGGTGAAGTCGTAAC
AAGGTAGCCGTAGGGGAACCTGCGGCTG 
 
>gi|694174373|gb|KM117186.1| 
Brucella melitensisstrain 46/VPH 16S 
ribosomal RNA gene (100%) 
 
 
 
6.2 PROTEIN BIOINFORMATICS RESULTS 
6.2.1 BLASTP ALIGNMENT RESULTS 
The BLASTP alignment tool (protein-protein BLAST 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) detected the following matching 
scoresbetweenBrucella protein and the corresponding Yersinia one: 
 
Protein %Identities 
isocitratelyase 61 
enoyl-CoA hydratase 63 
sugar-binding periplasmic protein -- 
Periplasmic Dipeptide TransportProtein 72 
Coml, Competence Lipoprotein -- 
molecularchaperoneDnaK 64 
Catalase 64 
ribose transport system substrate-binding protein  76 
sn-glycerol-3-phosphate-binding periplasmic protein ugpB 67 
glutamine amidotransferase 73 
 
No significant similarity was found between two Brucella and Yersinia proteins, Sugar-binding 
periplasmic protein andCompetence Lipoprotein, since blastp cannot find any reliable alignment, proving  
they arespecific for Brucella protein set.  
6.2.2 MHCI BINDING PREDICTIONRESULTS 
Protein 1:BRUME sugar-binding periplasmic protein 
Protein 2: Competence Lipoprotein 
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PROTEIN 1 RESULTS 
 
SP='YES' Cleavage site between pos. 27 and 28: ANA-QE D=0.821 D-cutoff=0.570 Networks=SignalP-
noTM 
 
-Prediction of the possibility that a peptide binds to mouse MHCI (all alleles, 11aa) 
http://tools.immuneepitope.org/mhci/result/ 
Allele # Start End Length Peptide Method used  Percentile 
rank 
H-2-
Db 
1 299 309 11 AVTFNSDMFAM Consensus 
(ann/smm) 
13 0.35 
H-2-
Db 
1 378 388 11 MAHGYANPAAV Consensus 
(ann/smm) 
7 1.45 
H-2-
Db 
1 140 150 11 AAPVNIHSTNW Consensus 
(ann/smm) 
10 1.45 
H-2-
Db 
1 106 116 11 GALGNLDTVAS Consensus 
(ann/smm) 
6+CD4 1.85 
H-2-
Db 
1 360 370 11 KAIADVKEANS Consensus 
(ann/smm) 
11 2.9 
H-2-
Db 
1 307 317 11 FAMFKVSEDKV Consensus 
(ann/smm) 
21 2.95 
H-2-
Db 
1 26 36 11 NAQEKQNVEVL Consensus 
(ann/smm) 
17 3.05 
H-2-
Db 
1 22 32 11 APVANAQEKQN Consensus 
(ann/smm) 
20 3.1 
H-2-
Db 
1 382 392 11 YANPAAVKNAI Consensus 
(ann/smm) 
16 4.35 
H-2-
Db 
1 325 335 11 SAIESPAFQSA Consensus 
(ann/smm) 
15 4.75 
H-2-
Db 
1 256 266 11 SAMVIEGKAGV Consensus 
(ann/smm) 
8+CD4 4.8 
H-2-
Db 
1 141 151 11 APVNIHSTNWM Consensus 
(ann/smm) 
3 5.6 
H-2-
Db 
1 390 400 11 NAIYDVVTRQF Consensus 
(ann/smm) 
5 5.85 
H-2-
Db 
1 84 94 11 TAGNAPTAVQM Consensus 
(ann/smm) 
9+CD4 6.05 
H-2-
Db 
1 352 362 11 TAFDACGKKAI Consensus 
(ann/smm) 
22 6.95 
H-2-
Db 
1 400 410 11 FNGQLSSEDAV Consensus 
(ann/smm) 
23 7.05 
H-2-
Db 
1 87 97 11 NAPTAVQMLGF Consensus 
(ann/smm) 
19+CD4 7.7 
H-2-
Db 
1 298 308 11 GAVTFNSDMFA Consensus 
(ann/smm) 
14 8.3 
H-2-
Db 
1 131 141 11 FAKYDGHWIAA Consensus 
(ann/smm) 
1 8.6 
H-2-
Db 
1 174 184 11 ALLDNFKAQGI Consensus 
(ann/smm) 
18 8.85 
H-2-
Db 
1 248 258 11 SGRDWNLASAM Consensus 
(ann/smm) 
4+CD4 8.85 
H-2-
Db 
1 214 224 11 KAFIDLDPEAL Consensus 
(ann/smm) 
2+CD4 9.15 
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NOTE: If the query includes all the alleles and all the lengths, the result can not be interpreted (too much 
information). Reducing the aa number to 11 , and maintaining  all the alleles, the table is analyzed, 
although all the compatible percentile rank values  affect the H-2-Db allele. 
-Prediction  of the relative ability of a peptide/MHC complex to elicit an immune response. 
(http://tools.iedb.org/immunogenicity) 
Immunogenicity predictions - Prediction Results 
Masking: default  
Masked variables: [1, 2, 'cterm']  
Predictions: 
 
Peptide Length Score  
FAKYDGHWIAA  11 0.35607 1 
KAFIDLDPEAL 11 0.30124 2 
APVNIHSTNWM  11 0.16739 3 
SGRDWNLASAM 11 0.15779 4 
NAIYDVVTRQF  11 0.15402 5 
GALGNLDTVAS  11 0.12924 6 
MAHGYANPAAV  11 0.11824 7 
SAMVIEGKAGV  11 0.09446 8 
TAGNAPTAVQM  11 0.07358 9 
AAPVNIHSTNW  11 0.06599 10 
KAIADVKEANS  11 0.05786 11 
AAVKNAIYDVV  11 -0.00284 12 
AVTFNSDMFAM  11 -0.05904 13 
GAVTFNSDMFA  11 -0.05986 14 
SAIESPAFQSA  11 -0.07407 15 
YANPAAVKNAI  11 -0.08246 16 
NAQEKQNVEVL  11 -0.11847 17 
ALLDNFKAQGI  11 -0.12471 18 
NAPTAVQMLGF 11 -0.1539 19 
APVANAQEKQN  11 -0.18366 20 
FAMFKVSEDKV  11 -0.28313 21 
TAFDACGKKAI  11 -0.28322 22 
FNGQLSSEDAV  11 -0.30273 23 
 
PROTEIN2 RESULTS 
Networks=noSignalP-noTM 
Allele # Start End Length Peptide Method used  Percentile 
rank 
H-2-
Ld 
1 139 149 11 SPESAYAYYII ann 19 0.2 
H-2-
Dd 
1 138 148 11 TSPESAYAYYI ann 21 0.4 
H-2-
Ld 
1 99 109 11 HPYTEWARKAL ann 3+CD4 0.4 
H-2-
Kd 
1 100 110 11 PYTEWARKALV Consensus 
(ann/smm) 
4+CD4 0.75 
H-2- 1 287 297 11 LQPRENGNSWL ann 9+CD4 0.9 
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Dd 
H-2-
Kd 
1 61 71 11 KYVETIDPADK Consensus 
(ann/smm) 
1 0.95 
H-2-
Dd 
1 18 28 11 RAGDRMTSFKF ann 46 1.2 
H-2-
Dd 
1 202 212 11 AGKEMQIGRYY ann 27 1.5 
H-2-
Ld 
1 144 154 11 YAYYIIGLSYF ann 10+CD4 1.7 
H-2-
Ld 
1 269 279 11 FPDSQWYKDSY ann 48 1.7 
H-2-
Kk 
1 85 95 11 LDEAAKKFAAI Consensus 
(ann/smm) 
38 1.8 
H-2-
Db 
1 164 174 11 QAASRRAIAAM Consensus 
(ann/smm) 
8+CD4 1.9 
H-2-
Kd 
1 274 284 11 WYKDSYKLLQS Consensus 
(ann/smm) 
51+CD4 2.1 
H-2-
Dd 
1 144 154 11 YAYYIIGLSYF ann  2.1 
H-2-
Dd 
1 67 77 11 DPADKLYNEGL ann 32 2.2 
H-2-
Ld 
1 244 254 11 RLVEAYYALGL ann 5 2.2 
H-2-
Db 
1 250 260 11 YALGLTSEAQM Consensus 
(ann/smm) 
26+CD4+++ 2.35 
H-2-
Kd 
1 26 36 11 FKFTGVTKTAL Consensus 
(ann/smm) 
14 2.4 
H-2-
Kk 
1 184 194 11 SEYTDDAKTKI Consensus 
(ann/smm) 
42+43 2.4 
H-2-
Ld 
1 136 146 11 YPTSPESAYAY ann 41 2.6 
H-2-
Dd 
1 265 275 11 LGKNFPDSQWY ann 30 2.8 
H-2-
Db 
1 112 122 11 AAFTNYRKGNY Consensus(ann/smm) 30 2.85 
H-2-
Dd 
1 127 137 11 SMAKRYNTLYP ann 37 2.9 
H-2-
Kk 
1 31 41 11 VTKTALLSGTI Consensus 
(ann/smm) 
36 3.05 
H-2-
Kd 
1 211 221 11 YYLERKEYLAA Consensus 
(ann/smm) 
13 3.15 
H-2-
Dd 
1 135 145 11 LYPTSPESAYA ann 39+40 3.2 
H-2-
Kd 
1 184 194 11 SEYTDDAKTKI Consensus 
(ann/smm) 
 3.3 
H-2-
Kd 
1 121 131 11 NYEEAISMAKR Consensus 
(ann/smm) 
35 3.35 
H-2-
Dd 
1 98 108 11 QHPYTEWARKA ann 2 3.4 
H-2-
Dd 
1 259 269 11 QMAASVLGKNF ann 47 3.4 
H-2-
Kb 
1 277 287 11 DSYKLLQSGGL Consensus 
(ann/smm) 
49+50+CD4+++ 3.55 
H-2- 1 50 60 11 CASKNDDIDLT Consensus 33 3.6 
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Db (ann/smm) 
H-2-
Kd 
1 135 145 11 LYPTSPESAYA Consensus 
(ann/smm) 
 3.75 
H-2-
Kk 
1 294 304 11 NSWLAKAGALI Consensus 
(ann/smm) 
25 3.75 
H-2-
Dd 
1 277 287 11 DSYKLLQSGGL ann  3.8 
H-2-
Dd 
1 292 302 11 NGNSWLAKAGA ann 29 4.1 
H-2-
Dd 
1 82 92 11 AGRLDEAAKKF ann 34 4.2 
H-2-
Dd 
1 156 166 11 QIPDVTRDQAA ann 12+CD4 4.3 
H-2-
Kd 
1 15 25 11 RYQRAGDRMTS Consensus 
(ann/smm) 
16 4.6 
H-2-
Dd 
1 268 278 11 NFPDSQWYKDS ann 45 4.7 
H-2-
Kd 
1 152 162 11 SYFRQIPDVTR Consensus 
(ann/smm) 
7 4.75 
H-2-
Kb 
1 149 159 11 IGLSYFRQIPD Consensus 
(ann/smm) 
24 5.05 
H-2-
Dd 
1 209 219 11 GRYYLERKEYL ann 18 5.2 
H-2-
Dd 
1 171 181 11 IAAMQEVIDRF ann 15 5.3 
H-2-
Dd 
1 201 211 11 LAGKEMQIGRY ann 44 5.3 
H-2-
Kk 
1 161 171 11 TRDQAASRRAI Consensus 
(ann/smm) 
31+CD4++ 5.4 
H-2-
Ld 
1 147 157 11 YIIGLSYFRQI ann 23+CD4 5.5 
H-2-
Kb 
1 115 125 11 TNYRKGNYEEA Consensus 
(ann/smm) 
20 5.65 
H-2-
Kk 
1 212 222 11 YLERKEYLAAI Consensus 
(ann/smm) 
17 5.7 
H-2-
Kd 
1 143 153 11 AYAYYIIGLSY Consensus 
(ann/smm) 
6+CD4 6.0 
NOTE: also in this case  the query involves all the alleles, but there is more variability 
 
-Prediction  of the relative ability of a peptide/MHC complex to elicit an immune response. 
(http://tools.iedb.org/immunogenicity) 
 
Immunogenicity predictions - Prediction Results 
Masking: default  
Masked variables: [1, 2, 'cterm']  
Predictions: 
 
Peptide Length Score  
KYVETIDPADK  11 0.33869 1 
QHPYTEWARKA  11 0.29819 2 
HPYTEWARKAL 11 0.27874 3 
PYTEWARKALV 11 0.24109 4 
RLVEAYYALGL  11 0.19232 5 
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AYAYYIIGLSY  11 0.19046 6 
SYFRQIPDVTR  11 0.17448 7 
QAASRRAIAAM 11 0.16629 8 
LQPRENGNSWL 11 0.15639 9 
YAYYIIGLSYF 11 0.13506 10 
YAYYIIGLSYF  11 0.13506 11 
QIPDVTRDQAA  11 0.0931 12 
YYLERKEYLAA  11 0.04507 13 
FKFTGVTKTAL  11 0.04068 14 
IAAMQEVIDRF  11 0.03514 15 
RYQRAGDRMTS  11 0.03038 16 
YLERKEYLAAI  11 0.01392 17 
GRYYLERKEYL  11 0.01152 18 
SPESAYAYYII  11 0.00979 19 
TNYRKGNYEEA  11 0.0071 20 
TSPESAYAYYI  11 0.0021 21 
YIIGLSYFRQI  11 -0.012 23 
IGLSYFRQIPD  11 -0.01247 24 
NSWLAKAGALI  11 -0.01462 25 
YALGLTSEAQM 11 -0.04401 26 
AGKEMQIGRYY  11 -0.05003 27 
AAFTNYRKGNY  11 -0.06062 28 
NGNSWLAKAGA  11 -0.07575 29 
LGKNFPDSQWY 11 -0.07578 30 
TRDQAASRRAI  11 -0.079 31 
DPADKLYNEGL  11 -0.09117 32 
CASKNDDIDLT  11 -0.09628 33 
AGRLDEAAKKF  11 -0.10833 34 
NYEEAISMAKR  11 -0.11843 35 
VTKTALLSGTI  11 -0.11889 36 
SMAKRYNTLYP  11 -0.13878 37 
LDEAAKKFAAI  11 -0.14395 38 
LYPTSPESAYA  11 -0.16381 39 
LYPTSPESAYA  11 -0.16381 40 
YPTSPESAYAY  11 -0.1717 41 
SEYTDDAKTKI  11 -0.17708 42 
SEYTDDAKTKI  11 -0.17708 43 
LAGKEMQIGRY  11 -0.20818 44 
NFPDSQWYKDS  11 -0.212 45 
RAGDRMTSFKF  11 -0.23241 46 
QMAASVLGKNF  11 -0.23351 47 
FPDSQWYKDSY  11 -0.34091 48 
DSYKLLQSGGL 11 -0.45993 49 
DSYKLLQSGGL 11 -0.45993 50 
WYKDSYKLLQS 11 -0.50986 51 
 
6.2.3 MHCII BINDING PREDICTION RESULTS 
PROTEIN 1 RESULTS 
http://tools.immuneepitope.org/mhcii/ 
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# Start End Peptide Method used  Percentile 
rank 
1 406 420 SEDAVKELVVAVEAA Consensus 
(comb.lib./smm/nn) 
21 0.09 
1 407 421 EDAVKELVVAVEAAK Consensus 
(comb.lib./smm/nn) 
19 0.10 
1 70 84 GGGTEAMTVLRARVT Consensus 
(comb.lib./smm/nn) 
20 0.31 
1 69 83 GGGGTEAMTVLRARV Consensus 
(comb.lib./smm/nn) 
25 0.33 
1 71 85 GGTEAMTVLRARVTA Consensus 
(comb.lib./smm/nn) 
18 0.39 
1 1 15 MHKLLKLAAMGTAAC Consensus 
(comb.lib./smm/nn) 
 0.42 
1 2 16 HKLLKLAAMGTAACA Consensus 
(comb.lib./smm/nn) 
 0.42 
1 68 82 AGGGGTEAMTVLRAR Consensus 
(comb.lib./smm/nn) 
28 0.42 
1 197 211 ATIFDAVVLSFGPDF Consensus 
(smm/nn/sturniolo) 
15 0.44 
1 201 215 DAVVLSFGPDFYKKA Consensus 
(smm/nn/sturniolo) 
 0.48 
1 199 213 IFDAVVLSFGPDFYK Consensus 
(smm/nn/sturniolo) 
30 0.51 
1 200 214 FDAVVLSFGPDFYKK Consensus 
(smm/nn/sturniolo) 
39 0.51 
1 198 212 TIFDAVVLSFGPDFY Consensus 
(smm/nn/sturniolo) 
21 0.52 
1 9 23 AMGTAACALLAGMAP Consensus 
(comb.lib./smm/nn) 
40 0.67 
1 192 206 QPWQDATIFDAVVLS Consensus 
(comb.lib./smm/nn) 
8 0.86 
1 191 205 GQPWQDATIFDAVVL Consensus 
(comb.lib./smm/nn) 
3 0.87 
1 8 22 AAMGTAACALLAGMA Consensus 
(comb.lib./smm/nn) 
 1.05 
1 214 228 KAFIDLDPEALGSDT Consensus 
(smm/nn/sturniolo) 
 1.16 
1 5 19 LKLAAMGTAACALLA Consensus 
(comb.lib./smm/nn) 
 1.22 
1 165 179 EPTNWDELIALLDNF Consensus 
(comb.lib./smm/nn) 
6 1.23 
1 202 216 AVVLSFGPDFYKKAF Consensus 
(smm/nn/sturniolo) 
 1.24 
1 10 24 MGTAACALLAGMAPV Consensus 
(comb.lib./smm/nn) 
 1.25 
1 193 207 PWQDATIFDAVVLSF Consensus 
(comb.lib./smm/nn) 
12 1.33 
1 166 180 PTNWDELIALLDNFK Consensus 
(comb.lib./smm/nn) 
4 1.36 
1 194 208 WQDATIFDAVVLSFG Consensus 
(comb.lib./smm/nn) 
9 1.38 
1 167 181 TNWDELIALLDNFKA Consensus 
(comb.lib./smm/nn) 
13 1.43 
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1 7 21 LAAMGTAACALLAGM Consensus 
(comb.lib./smm/nn) 
 1.46 
1 6 20 KLAAMGTAACALLAG Consensus 
(comb.lib./smm/nn) 
 1.56 
1 67 81 VAGGGGTEAMTVLRA Consensus 
(comb.lib./smm/nn) 
29 1.62 
1 203 217 VVLSFGPDFYKKAFI Consensus 
(smm/nn/sturniolo) 
 1.63 
1 164 178 KEPTNWDELIALLDN Consensus 
(comb.lib./smm/nn) 
5 1.68 
1 250 264 RDWNLASAMVIEGKA Consensus 
(comb.lib./smm/nn) 
 1.73 
1 213 227 KKAFIDLDPEALGSD Consensus 
(smm/nn/sturniolo) 
 1.73 
1 249 263 GRDWNLASAMVIEGK Consensus 
(comb.lib./smm/nn) 
23+24 1.75 
1 251 265 DWNLASAMVIEGKAG Consensus 
(comb.lib./smm/nn) 
 1.79 
1 215 229 AFIDLDPEALGSDTM Consensus 
(smm/nn/sturniolo) 
36 1.99 
1 72 86 GTEAMTVLRARVTAG Consensus 
(comb.lib./smm/nn) 
31 2.01 
1 3 17 KLLKLAAMGTAACAL Consensus 
(comb.lib./smm/nn) 
 2.05 
1 4 18 LLKLAAMGTAACALL Consensus 
(comb.lib./smm/nn) 
 2.05 
1 73 87 TEAMTVLRARVTAGN Consensus 
(comb.lib./smm/nn) 
34 2.06 
1 405 419 SSEDAVKELVVAVEA Consensus 
(comb.lib./smm/nn) 
27 2.11 
1 330 344 PAFQSAFNVVKGSAP Consensus 
(smm/nn/sturniolo) 
 2.15 
1 329 343 SPAFQSAFNVVKGSA Consensus 
(smm/nn/sturniolo) 
 2.21 
1 328 342 ESPAFQSAFNVVKGS Consensus 
(smm/nn/sturniolo) 
 2.26 
1 327 341 IESPAFQSAFNVVKG Consensus 
(smm/nn/sturniolo) 
 2.28 
1 118 132 EGWEKVIPAPLQEFA Consensus 
(comb.lib./smm/nn) 
33 2.28 
1 326 340 AIESPAFQSAFNVVK Consensus 
(smm/nn/sturniolo) 
 2.37 
1 117 131 KEGWEKVIPAPLQEF Consensus 
(comb.lib./smm/nn) 
16 2.39 
1 2 16 HKLLKLAAMGTAACA Consensus 
(comb.lib./smm/nn) 
 2.40 
1 83 97 VTAGNAPTAVQMLGF Consensus 
(comb.lib./smm/nn) 
 2.40 
1 84 98 TAGNAPTAVQMLGFD Consensus 
(comb.lib./smm/nn) 
 2.40 
1 3 17 KLLKLAAMGTAACAL Consensus 
(comb.lib./smm/nn) 
 2.43 
1 252 266 WNLASAMVIEGKAGV Consensus 
(comb.lib./smm/nn) 
 2.43 
29 
 
1 4 18 LLKLAAMGTAACALL Consensus 
(comb.lib./smm/nn) 
 2.45 
1 248 262 SGRDWNLASAMVIEG Consensus 
(comb.lib./smm/nn) 
 2.51 
1 249 263 GRDWNLASAMVIEGK Consensus 
(comb.lib./smm/nn) 
23+24 2.51 
1 105 119 QGALGNLDTVASKEG Consensus 
(smm/nn/sturniolo) 
 2.54 
1 335 349 AFNVVKGSAPARTDV Consensus 
(smm/nn/sturniolo) 
 2.55 
1 106 120 GALGNLDTVASKEGW Consensus 
(smm/nn/sturniolo) 
 2.59 
1 336 350 FNVVKGSAPARTDVP Consensus 
(smm/nn/sturniolo) 
 2.61 
1 104 118 EQGALGNLDTVASKE Consensus 
(smm/nn/sturniolo) 
 2.66 
1 334 348 SAFNVVKGSAPARTD Consensus 
(smm/nn/sturniolo) 
 2.69 
1 103 117 AEQGALGNLDTVASK Consensus 
(smm/nn/sturniolo) 
 2.70 
1 333 347 QSAFNVVKGSAPART Consensus 
(smm/nn/sturniolo) 
 2.70 
1 1 15 MHKLLKLAAMGTAAC Consensus 
(smm/nn/sturniolo) 
 2.76 
1 2 16 HKLLKLAAMGTAACA Consensus 
(smm/nn/sturniolo) 
 2.76 
1 3 17 KLLKLAAMGTAACAL Consensus 
(smm/nn/sturniolo) 
 2.81 
1 102 116 WAEQGALGNLDTVAS Consensus 
(smm/nn/sturniolo) 
 2.81 
1 212 226 YKKAFIDLDPEALGS Consensus 
(smm/nn/sturniolo) 
 2.81 
1 4 18 LLKLAAMGTAACALL Consensus 
(smm/nn/sturniolo) 
 2.87 
1 92 106 VQMLGFDIRDWAEQG Consensus 
(smm/nn/sturniolo) 
2 2.87 
1 91 105 AVQMLGFDIRDWAEQ Consensus 
(smm/nn/sturniolo) 
7 2.88 
1 90 104 TAVQMLGFDIRDWAE Consensus 
(smm/nn/sturniolo) 
14 2.89 
1 89 103 PTAVQMLGFDIRDWA Consensus 
(smm/nn/sturniolo) 
17 2.90 
1 93 107 QMLGFDIRDWAEQGA Consensus 
(smm/nn/sturniolo) 
1 2.93 
1 247 261 FSGRDWNLASAMVIE Consensus 
(comb.lib./smm/nn) 
 3 
1 1 15 MHKLLKLAAMGTAAC Consensus 
(comb.lib./smm/nn) 
 3 
Immunogenicity prediction ( Class I peptide) 
-Prediction  of the relative ability of a peptide/MHC complex to elicit an immune response. 
(http://tools.iedb.org/immunogenicity) 
 
Masking: default  
Masked variables: [1, 2, 'cterm']  
30 
 
Predictions: 
 
Peptide Length Score  
QMLGFDIRDWAEQGA  15 0.63779 1 
VQMLGFDIRDWAEQG  15 0.57139 2 
GQPWQDATIFDAVVL  15 0.56498 3 
PTNWDELIALLDNFK  15 0.55901 4 
KEPTNWDELIALLDN  15 0.51402 5 
EPTNWDELIALLDNF  15 0.49149 6 
AVQMLGFDIRDWAEQ  15 0.44513 7 
QPWQDATIFDAVVLS  15 0.42336 8 
WQDATIFDAVVLSFG  15 0.38641 9 
YKKAFIDLDPEALGS  15 0.37934 10 
KKAFIDLDPEALGSD  15 0.3388 11 
PWQDATIFDAVVLSF  15 0.33696 12 
TNWDELIALLDNFKA  15 0.31533 13 
TAVQMLGFDIRDWAE  15 0.29432 14 
ATIFDAVVLSFGPDF  15 0.2787 15 
KEGWEKVIPAPLQEF  15 0.25799 16 
PTAVQMLGFDIRDWA  15 0.2547 17 
GGTEAMTVLRARVTA  15 0.24239 18 
EDAVKELVVAVEAAK  15 0.23977 19 
GGGTEAMTVLRARVT  15 0.23689 20 
TIFDAVVLSFGPDFY  15 0.2306 21 
SEDAVKELVVAVEAA  15 0.22819 22 
GRDWNLASAMVIEGK 15 0.22687 23 
GRDWNLASAMVIEGK 15 0.22687 24 
GGGGTEAMTVLRARV  15 0.22668 25 
KAFIDLDPEALGSDT  15 0.22356 26 
SSEDAVKELVVAVEA  15 0.22039 27 
AGGGGTEAMTVLRAR  15 0.2146 28 
VAGGGGTEAMTVLRA  15 0.21104 29 
IFDAVVLSFGPDFYK  15 0.20879 30 
GTEAMTVLRARVTAG  15 0.20145 31 
SGRDWNLASAMVIEG  15 0.1915 32 
EGWEKVIPAPLQEFA  15 0.18201 33 
TEAMTVLRARVTAGN  15 0.17166 34 
FSGRDWNLASAMVIE 15 0.14568 35 
AFIDLDPEALGSDTM  15 0.10899 36 
WAEQGALGNLDTVAS 15 0.10798 37 
AEQGALGNLDTVASK  15 0.07432 38 
FDAVVLSFGPDFYKK  15 0.06142 39 
AMGTAACALLAGMAP  15 0.03492 40 
LKLAAMGTAACALLA  15 0.01836 41 
AAMGTAACALLAGMA  15 0.01793 42 
KLAAMGTAACALLAG  15 0.01673 43 
LAAMGTAACALLAGM  15 0.00018 44 
MGTAACALLAGMAPV  15 -0.01359 45 
RDWNLASAMVIEGKA  15 -0.03466 46 
QSAFNVVKGSAPART  15 -0.04258 47 
TAGNAPTAVQMLGFD  15 -0.04935 48 
LLKLAAMGTAACALL  15 -0.05317 49 
LLKLAAMGTAACALL  15 -0.05317 50 
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LLKLAAMGTAACALL  15 -0.05317 51 
ESPAFQSAFNVVKGS  15 -0.06147 52 
AIESPAFQSAFNVVK  15 -0.0616 53 
EQGALGNLDTVASKE  15 -0.07372 54 
VTAGNAPTAVQMLGF  15 -0.08376 55 
FNVVKGSAPARTDVP  15 -0.08798 56 
IESPAFQSAFNVVKG  15 -0.09316 57 
SAFNVVKGSAPARTD  15 -0.09572 58 
AFNVVKGSAPARTDV  15 -0.09862 59 
WNLASAMVIEGKAGV 15 -0.10811 60 
GALGNLDTVASKEGW  15 -0.1087 61 
QGALGNLDTVASKEG  15 -0.12409 62 
DWNLASAMVIEGKAG  15 -0.1291 63 
DAVVLSFGPDFYKKA  15 -0.15664 64 
SPAFQSAFNVVKGSA  15 -0.18826 65 
KLLKLAAMGTAACAL  15 -0.20311 66 
KLLKLAAMGTAACAL  15 -0.20311 67 
KLLKLAAMGTAACAL  15 -0.20311 68 
VVLSFGPDFYKKAFI  15 -0.21345 69 
HKLLKLAAMGTAACA  15 -0.22121 70 
HKLLKLAAMGTAACA  15 -0.22121 71 
HKLLKLAAMGTAACA  15 -0.22121 72 
AVVLSFGPDFYKKAF  15 -0.2528 73 
MHKLLKLAAMGTAAC  15 -0.28214 74 
MHKLLKLAAMGTAAC  15 -0.28214 75 
MHKLLKLAAMGTAAC  15 -0.28214 76 
PAFQSAFNVVKGSAP  15 -0.30832 77 
 
PROTEIN 2 RESULTS 
http://tools.immuneepitope.org/mhcii/ 
 
# Start End Peptide Method used  Percentile 
rank 
1 251 265 ALGLTSEAQMAASVL Consensus 
(comb.lib./smm/nn) 
 0.77 
1 252 266 LGLTSEAQMAASVLG Consensus 
(comb.lib./smm/nn) 
 0.85 
1 276 290 KDSYKLLQSGGLQPR Consensus 
(comb.lib./smm/nn) 
 0.96 
1 100 114 PYTEWARKALVMAAF Consensus 
(comb.lib./smm/nn) 
 1.19 
1 101 115 YTEWARKALVMAAFT Consensus 
(comb.lib./smm/nn) 
13 1.19 
1 102 116 TEWARKALVMAAFTN Consensus 
(comb.lib./smm/nn) 
 1.19 
1 103 117 EWARKALVMAAFTNY Consensus 
(comb.lib./smm/nn) 
 1.21 
1 274 288 WYKDSYKLLQSGGLQ Consensus 
(comb.lib./smm/nn) 
 1.33 
1 277 291 DSYKLLQSGGLQPRE Consensus  1.33 
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(comb.lib./smm/nn) 
1 235 249 TRQVEEALARLVEAY Consensus 
(comb.lib./smm/nn) 
2 1.33 
1 157 171 IPDVTRDQAASRRAI Consensus 
(smm/nn/sturniolo) 
 1.40 
1 236 250 RQVEEALARLVEAYY Consensus 
(comb.lib./smm/nn) 
1 1.42 
1 253 267 GLTSEAQMAASVLGK Consensus 
(comb.lib./smm/nn) 
 1.47 
1 275 289 YKDSYKLLQSGGLQP Consensus 
(comb.lib./smm/nn) 
 1.53 
1 154 168 FRQIPDVTRDQAASR Consensus 
(smm/nn/sturniolo) 
19 1.59 
1 155 169 RQIPDVTRDQAASRR Consensus 
(smm/nn/sturniolo) 
 1.59 
1 156 170 QIPDVTRDQAASRRA Consensus 
(smm/nn/sturniolo) 
 1.59 
1 158 172 PDVTRDQAASRRAIA Consensus 
(smm/nn/sturniolo) 
17 1.59 
1 159 173 DVTRDQAASRRAIAA Consensus 
(smm/nn/sturniolo) 
16 1.59 
1 160 174 VTRDQAASRRAIAAM Consensus 
(smm/nn/sturniolo) 
 1.59 
1 148 162 IIGLSYFRQIPDVTR Consensus 
(smm/nn/sturniolo) 
20 1.89 
1 237 251 QVEEALARLVEAYYA Consensus 
(comb.lib./smm/nn) 
3 1.92 
1 149 163 IGLSYFRQIPDVTRD Consensus 
(smm/nn/sturniolo) 
18 1.93 
1 99 113 HPYTEWARKALVMAA Consensus 
(comb.lib./smm/nn) 
 1.94 
1 151 165 LSYFRQIPDVTRDQA Consensus 
(smm/nn/sturniolo) 
6 1.97 
1 150 164 GLSYFRQIPDVTRDQ Consensus 
(smm/nn/sturniolo) 
7 2.03 
1 254 268 LTSEAQMAASVLGKN Consensus 
(comb.lib./smm/nn) 
 2.28 
1 152 166 SYFRQIPDVTRDQAA Consensus 
(smm/nn/sturniolo) 
11 2.46 
1 273 287 QWYKDSYKLLQSGGL Consensus 
(comb.lib./smm/nn) 
 2.46 
1 238 252 VEEALARLVEAYYAL Consensus 
(comb.lib./smm/nn) 
5 2.49 
1 246 260 VEAYYALGLTSEAQM Consensus 
(smm/nn/sturniolo) 
 2.56 
1 247 261 EAYYALGLTSEAQMA Consensus 
(smm/nn/sturniolo) 
 2.61 
1 34 48 TALLSGTIAVLIPLA Consensus 
(comb.lib./smm/nn) 
10 2.66 
1 248 262 AYYALGLTSEAQMAA Consensus 
(smm/nn/sturniolo) 
 2.68 
1 190 204 AKTKIRVARDQLAGK Consensus 
(smm/nn/sturniolo) 
 2.71 
1 191 205 KTKIRVARDQLAGKE Consensus  2.71 
33 
 
(smm/nn/sturniolo) 
1 192 206 TKIRVARDQLAGKEM Consensus 
(smm/nn/sturniolo) 
 2.71 
1 193 207 KIRVARDQLAGKEMQ Consensus 
(smm/nn/sturniolo) 
 2.71 
1 194 208 IRVARDQLAGKEMQI Consensus 
(smm/nn/sturniolo) 
 2.71 
1 163 177 DQAASRRAIAAMQEV Consensus 
(comb.lib./smm/nn) 
 2.74 
1 250 264 YALGLTSEAQMAASV Consensus 
(comb.lib./smm/nn) 
 2.76 
1 234 248 NTRQVEEALARLVEA Consensus 
(comb.lib./smm/nn) 
4 2.90 
1 143 157 AYAYYIIGLSYFRQI Consensus 
(smm/nn/sturniolo) 
 2.92 
1 249 263 YYALGLTSEAQMAAS Consensus 
(comb.lib./smm/nn) 
 2.94 
1 164 178 QAASRRAIAAMQEVI Consensus 
(comb.lib./smm/nn) 
 2.96 
1 35 49 ALLSGTIAVLIPLAG Consensus 
(comb.lib./smm/nn) 
8 3 
Immunogenicity prediction (Class I peptide) 
-Prediction  of the relative ability of a peptide/MHC complex to elicit an immune response. 
(http://tools.iedb.org/immunogenicity) 
 
Masking: default  
Masked variables: [1, 2, 'cterm']  
 
Predictions: 
Peptide Length Score  
RQVEEALARLVEAYY  15 0.48196 1 
TRQVEEALARLVEAY  15 0.45016 2 
QVEEALARLVEAYYA  15 0.4075 3 
NTRQVEEALARLVEA  15 0.33414 4 
VEEALARLVEAYYAL  15 0.33083 5 
LSYFRQIPDVTRDQA  15 0.27236 6 
GLSYFRQIPDVTRDQ  15 0.26796 7 
ALLSGTIAVLIPLAG  15 0.23049 8 
AYAYYIIGLSYFRQI  15 0.20828 9 
TALLSGTIAVLIPLA  15 0.20148 10 
SYFRQIPDVTRDQAA  15 0.19206 11 
HPYTEWARKALVMAA  15 0.17038 12 
YTEWARKALVMAAFT  15 0.16864 13 
PYTEWARKALVMAAF  15 0.16563 14 
VTRDQAASRRAIAAM 15 0.16148 15 
DVTRDQAASRRAIAA  15 0.16139 16 
PDVTRDQAASRRAIA  15 0.13666 17 
IGLSYFRQIPDVTRD  15 0.12019 18 
FRQIPDVTRDQAASR  15 0.11751 19 
IIGLSYFRQIPDVTR  15 0.08394 20 
KTKIRVARDQLAGKE  15 0.08045 21 
IPDVTRDQAASRRAI  15 0.0761 22 
TKIRVARDQLAGKEM  15 0.06848 23 
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RQIPDVTRDQAASRR  15 0.05639 24 
AKTKIRVARDQLAGK  15 0.05548 25 
QIPDVTRDQAASRRA  15 0.05031 26 
TEWARKALVMAAFTN  15 0.04458 27 
DQAASRRAIAAMQEV  15 0.03111 28 
QAASRRAIAAMQEVI  15 0.01951 29 
VEAYYALGLTSEAQM 15 -0.00883 30 
EWARKALVMAAFTNY  15 -0.03334 31 
KIRVARDQLAGKEMQ  15 -0.10516 32 
EAYYALGLTSEAQMA  15 -0.14475 33 
AYYALGLTSEAQMAA  15 -0.17251 34 
YYALGLTSEAQMAAS  15 -0.18618 35 
IRVARDQLAGKEMQI  15 -0.25936 36 
YALGLTSEAQMAASV  15 -0.27861 37 
ALGLTSEAQMAASVL  15 -0.31223 38 
LGLTSEAQMAASVLG  15 -0.32501 39 
GLTSEAQMAASVLGK  15 -0.33767 40 
LTSEAQMAASVLGKN  15 -0.35119 41 
DSYKLLQSGGLQPRE  15 -0.54666 42 
KDSYKLLQSGGLQPR  15 -0.6116 43 
WYKDSYKLLQSGGLQ  15 -0.66386 44 
YKDSYKLLQSGGLQP  15 -0.68051 45 
QWYKDSYKLLQSGGL  15 -0.81303 46 
 
6.2.4 ANTIBODY EPITOPE PREDICTION RESULTS 
Bepipred Linear Epitope Prediction 
Average:0.152   Minimum:-1.618   Maximum:1.742   Threshold:
0.350
 
PROTEIN 1 RESULTS 
Predicted epitopes: 
No. Start Position End Position Peptide Peptide Length 
1 23 31 PVANAQEKQ 9 
2 41 46 SGGEAS 6 
3 55 58 LESK 4 
4 60 62 ISW 3 
5 64 74 DMPVAGGGGTE 11 
6 84 90 TAGNAPT 7 
7 102 109 WAEQGALG 8 
8 113 123 TVASKEGWEKV 11 
9 125 126 PA 2 
10 129 129 Q 1 
11 131 133 FAK 3 
12 145 145 I 1 
13 158 169 LDKAGGKEPTNW 12 
14 181 182 AQ 2 
15 184 197 ITPIAHGGQPWQDA 14 
16 210 210 D 1 
17 221 231 PEALGSDTMKQ 11 
18 244 250 DDNFSGR 7 
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19 252 252 W 1 
20 278 286 LKAGKKPGE 9 
21 294 301 PGTQGAVT 8 
22 314 319 EDKVPA 6 
23 326 332 AIESPAF 7 
24 340 356 KGSAPARTDVPDTAFDA 17 
25 363 371 ADVKEANSK 9 
26 380 388 HGYANPAAV 9 
27 402 409 GQLSSEDA 8 
 
PROTEIN 2 RESULTS 
Predicted epitopes: 
No. Start Position End Position Peptide Peptide Length 
1 1 3 MRS 3 
2 15 22 RYQRAGDR 8 
3 50 58 CASKNDDID 9 
4 64 73 ETIDPADKLY 10 
5 83 88 GRLDEA 6 
6 97 104 RQHPYTEW 8 
7 117 124 YRKGNYEE 8 
8 134 143 TLYPTSPESA 10 
9 159 167 DVTRDQAAS 9 
10 180 192 RFPNSEYTDDAKT 13 
11 201 203 LAG 3 
12 230 238 EEYSNTRQV 9 
13 259 259 Q 1 
14 267 276 KNFPDSQWYK 10 
15 286 297 GLQPRENGNSWL 12 
 
6.3 EXPERIMENTAL INFECTIONS RESULTS 
The Mann-Whitney test performed considering the differences of the ratios of the percentages of IFN-γ+ 
cells in response to Yersinia and Brucella antigens between the animals immunized with Yersinia vs those 
infected with Brucella, showed that the difference between the two set of values is statistically significant 
(p<0.05). The statistical analysis was also performed considering the ratios of the percentages of IFN-γ+ 
cells, CD4+ IFN-γ+ T cells and CD8+ IFN-γ+ T cells in response to Yersinia and Brucella antigens. 
Results obtained from animals immunized with Y. enterocolitica (Fig.1) showed an expansion of IFN-γ+ 
lymphocytes, following the re-exposure to YeO:9 (2.36% in immunized versus 0.36% in uninfected 
controls) but not to Brucella antigen (Fig.1A). The difference of IFN-γ production by cells stimulated by 
the two antigens is statistically significant. In details, the production of IFN-γ by CD4+ and CD8+ T cell 
subsets is similar, even if the role of CD4+ T cells in producing this cytokine is slightly higher (Fig.1B,C). 
This is the first evidence of a different behavior of T lymphocytes when stimulated with different antigens, 
that are normally cross-reactive.Results showed that γδ+ T-lymphocytes display a minor contribution to 
IFN-γ production, reaching 0.1% in response to YeO:9 and 0.01% in seronegative animals (Fig. 1D). 
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Fig. 1. Flow cytometric analysis in Yersinia-immunized animals: the 
antigen-specific stimulation resulted in a higher percentage of IFN-γ+ T-
lymphocytes (2.36%), compared with the same cells but stimulated with 
Brucella antigen (0.18% - Panel A). The detection of CD4+ IFN- γ+ T-
lymphocytes (Panel B) and CD8+ IFN-γ+ T-lymphocytes (Panel C) confirmed 
a similar contribute of these two subsets to total IFN-γ+ T-lymphocytes in the 
two experimental groups, with a slightly higher CD4+ T cells detection. γδ+ 
IFN-γ+ T cells detection (Panel D) amounted to 0.1 % in response to YeO:9 
and to 0.04% in seronegative animals. Experiments were repeated three times 
and data showed are the mean of different experiments.*p<0.05 
 
 
The results obtained by cattle naturally infected by Brucella (Fig.2), showeda good production of IFN-γ 
when cells were stimulated both by Brucella and Yersinia antigens (Fig.2A). Data showed that in the same 
animals IFN-γ+ lymphocytes are similarly present when in vitro exposed to Yersinia (5.99%) or Brucella 
stimulus (5.70%). The analysis of T-cell subsets showed that CD4+ T cells produce a similar percentage of 
IFN-γ+ in response to both antigens, thus confirming a cross-reactivity in cell-mediated immunity (Fig. 2B). 
The analysis of T cell subsets showed a higher production of IFN-γ by CD4+ T cells rather than CD8+ 
lymphocytes (Fig.2B,C). In details CD4+ IFN-γ+ T-cell subset expanded similarly in response to Yersinia 
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(2.96% for cattle positive for Brucella abortus and in vitro stimulated with Yersinia antigen) and Brucella 
(2.77% in vitro stimulated with Brucella antigen). We did not observe any significant statistic differences 
when CD8+ T cells (Fig.2C) were analyzed in response to the two antigens. Data regarding the analysis of 
γδ
+
 T cells revealed that the difference of IFN-γ production is not statistically significant between animals 
positive for Brucella and in vitro stimulated with the two antigens, but a statistically significant difference 
was detected when PBMC from infected and seronegative cattle were exposed to Yersinia. (Fig.2D). 
 
Fig. 2. Flow cytometric analysis in animals naturally infected by 
Brucella: IFN-γ+ T-cells detection is similar when cells are in 
vitroexposed to Yersinia (6.09%) or Brucella antigens (5.7%) (Panel A). 
CD4+ T cells (Fig. 2B) produce IFN-γ when exposed to both antigens 
(2,96% to Yersinia and 2,77% to Brucella). Statistical significances 
were assessed and percentages of IFN-γ+ and CD4+ IFN-γ+ T cells were 
compared to seronegative controls (1,20% when exposed to Yersinia 
and 1,45% to Brucella) (*p<0.05). No significant expansion of CD8+ 
(Panel C) and γδ+ IFN-γ+ T was observed in response to both the 
antigens (Panel D). Data shown are the mean of the percentages 
obtained in different experiments. 
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The immune response mounted by CD4+- and CD8+- IFN-γ+ CD45R0+ T cells in Yersinia-immunized 
animals was analyzed but no statistically significant expansions were found (data not shown). 
The analysis of memory cells producing IFN-γ in animals naturally infected with Brucella revealed that 
there is a statistically significant difference in the expansion of CD4+ IFN-γ+ CD45R0+ T cells when 
animals are stimulated with the two antigens: the amount of these cells is higher when stimulated with 
Yersinia than with Brucella antigens (Fig. 3A). CD8+ IFN-γ+ CD45R0+ T cells detection showed 
statistically significant difference after stimulation with both  antigens (Fig. 3B) 
 
 
Fig. 3. Analysis of IFN-γ-producing memory cells in animals naturally 
infected with Brucella: the amount of CD4+ IFN-γ+ CD45R0+ T cells 
detected is  statistically higher when in vitro stimulated with Yersinia antigen 
(10,27%) compared to Brucella antigen (6,13%) (panel A) (*p<0.05). CD8+ 
IFN-γ+ CD45R0+T cells detection shows there is no statistically significant 
difference after stimulation with Yersinia (7,685%) or Brucella antigens 
(7,11%), although it is higher in the Brucella seropositive than in the 
seronegative animals (panel B). 
The percentage of IFN-γ+ cells and the different pattern of response, exclusive for Yersinia antigen in 
animals immunized with YeO:9, could open a new possibility for the diagnostic determination of the two 
pathogens. 
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The bioinformatics studies allowed the selection of two proteins, based on different criteria including: 
- lenght 
- in silicostudies 
- nature and numerosity of B cell/Tcellepitopes  
- nature and abundance of epitopes for T cells 
We are evaluating to produce them in vitro or produce only some epitopesselected according to the 
following criteria: 
a. Best likelihood to be loaded onto MHCI or MHCII 
b. Best immunogenicity  
c. UNICITY : avoiding overlap so that each epitope didn’t stimulate both CD4 and / or CD8 
d. NO OVERLAPPING with linear B cell epitopes 
e. Exclusion of signal peptides 
 For each protein we selected four epitopes, two loaded onto MHCI and two onto MHCII 
Sugar-binding periplasmic protein: 
- MHC I peptids 
H-2-Db
 
H-2-Db 
1 378 388 11 MAHGYANPAAV Consensus (ann/smm) 7 1.45 
H-2-Db 1 140 150 11 AAPVNIHSTNW Consensus (ann/smm) 10 1.45 
 
- MHC II peptids 
1 192 206 QPWQDATIFDAVVLS Consensus (comb.lib./smm/nn) 8 0.86 
1 236 250 RQVEEALARLVEAYY Consensus (comb.lib./smm/nn) 1 1.42 
 
Competence Lipoprotein 
- MHC I peptids 
H-2-Kd 1 61 71 11 KYVETIDPADK Consensus 
(ann/smm) 
1 0.95 
H-2-Ld 1 244 254 11 RLVEAYYALGL ann 5 2.2 
 
- MHC II peptids 
1 192 206 QPWQDATIFDAVVLS Consensus 
(comb.lib./smm/nn) 
8 0.86 
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1 191 205 GQPWQDATIFDAVVL Consensus 
(comb.lib./smm/nn) 
3 0.87 
 
On the other side, the experimental work carried out allowed the detection, for the first time in cattle, of 
lymphocyte populations, CD4+ and CD8+ IFN-γ+ T cells, that expand differently when PBMC of animals 
immunized with Yersinia are in vitro exposed to Yersinia or to Brucella antigen. Even if the correspondent 
behavior cannot be detected in Brucella-infected animals, due to the persistent cross-reactivity between the 
two antigens, the analysis of the expansion of IFN-γ+ cells in response to Brucella and Y. enterocolitica 
antigens could be useful to distinguish between Yersinia and Brucella infection in cattle. Non-LPS Brucella 
proteins could be of paramount importance for the specific diagnosis of Brucella infection, since they allow 
to avoid cross-reactivity issues. 
Further research is needed on the identification, isolation, characterization and cloning of both inner and 
outer membrane proteins which could be used as diagnostic antigens that are more sensitive and specific. 
This should be followed by the development of subunit or live antigen-deleted vaccines, able to protect 
animals without interfering with diagnostic tests, and should be a major goal of research in the near future. 
The antigens obtained from the comparative analysis of bacterial protein patterns will be synthesized 
(whole protein or its peptides) and used for in vitro stimulation of lymphocytes obtained from Balb-c mice 
experimentally infected. These antigens will also be retested on the mouse model to verify their properties 
specific immunogenic. For this purpose, we will infect two groups of mice with Brucella melitensis and 
Yersinia enterocolitica strains respectively , according to Wang et al., 2013, and after scarification, we will 
withdraw the sera and the spleens. The sera will be used for the determination and eventual quantization of 
cytokine production; from spleens we will isolate lymphocytes, which will be cultured and in vitro 
stimulated with the antigens selected, in order to test their specificity. They will be treated by surface and 
intracytoplasmic markers (CD3, CD4, CD8, IFN-γ, CD69, CCR5) in order to compare, by flow cytometric 
analyses, the cell activation state and determine, for comparison, which cytokine (and/or which cell 
population) is specifically activated in samples from mice infected with Brucella, but not in samples from 
mice infected with Yersinia. 
The future research aims to verify, on one side, whether there are diagnostic protein antigens able to 
discriminate Brucella infection from other diseases, on the other hand, a pattern of lymphocyte activation, 
with relative cytokines production, which can be useful to increase the panel of available laboratory 
diagnostic tests. 
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